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The Epstein-Barr virus (EBV) BHLF1 gene encodes an abundant linear and several 
circular RNAs believed to perform non-coding functions during virus replication, though 
an open reading frame is retained among an unknown percentage of EBV isolates. 
Evidence suggests that BHLF1 is also transcribed during latent infection, which prompted 
us to investigate the contribution of this locus to latency. Analysis of transcripts transiting 
BHLF1 revealed its transcription is widespread among B-cell lines supporting the latency 
I or III program of EBV protein expression, and to be more complex than originally 
presumed. EBV-negative Burkitt lymphoma cell lines infected with either wild-type or two 
different BHLF1 mutant EBVs were initially indistinguishable in supporting latency III. 
However, cells infected with BHLF1- virus ultimately transitioned to the more restrictive 
latency I, whereas cells infected with wild-type virus either sustained latency III or 
transitioned more slowly to latency I. Upon infection of primary B cells, which require 
latency III for growth in vitro, both BHLF1- viruses exhibited variably reduced 
immortalization potential relative to wild-type virus. Finally, in transfection experiments, 
efficient protein expression from an intact BHLF1 ORF required the EBV post-
transcriptional regulator protein SM, whose expression is limited to the replicative cycle. 
Thus, one way in which BHLF1 may contribute to latency is through a mechanism, 
possibly mediated or regulated by a long non-coding RNA, that supports latency III critical 
for the establishment of EBV latency and lifelong persistence within its host, whereas any 




Epstein-Barr virus (EBV) has significant oncogenic potential that is linked to its latent 
infection of B lymphocytes, during which virus replication is not supported. Establishment 
of latent infection, which is life long and can precede tumor development by years, 
requires the concerted actions of nearly a dozen EBV proteins and numerous small non-
protein-coding RNAs. Elucidation of how these EBV products contribute to latency is 
crucial to understanding EBV’s role in specific malignancies, and ultimately to clinical 
intervention. Historically, EBV genes that contribute to virus replication have been 
excluded from consideration of a role in latency, primarily because of the general 
incompatibility between virus production and cell survival. However, here we provide 
evidence that the genetic locus containing one such gene, BHLF1, indeed contributes to 
key aspects of EBV latency, including its ability to promote continuous growth of B 





Epstein-Barr virus (EBV) is a potentially oncogenic herpesvirus able to persist for the 
life of its human host upon the establishment of a latent infection within B lymphocytes.  
The process through which this occurs is mediated through the concerted actions of a 
subset of EBV genes that are believed to direct a germinal center-like reaction, ultimately 
enabling infected cells to specifically enter the memory B-cell pool that serves as the 
primary reservoir of EBV, and from which virus replication can be periodically reactivated 
(1). Because EBV-positive tumors predominantly support latent infection, and virus 
replication (i.e., lytic infection) is generally incompatible with cell survival, elucidation of 
the contributions of EBV to its associated malignancies has primarily focused on the 
latency-associated genes. These are genes typically expressed exclusively during 
latency, although some are also expressed upon activation of the EBV replicative cycle 
(2-5). Conversely, the expression of EBV lytic-cycle genes within predominantly latently 
infected cell lines and tumors historically has been attributed to sporadic and often 
abortive reactivation of the virus replication cycle in a subpopulation of cells; 
consequently, their potential contribution to EBV latency and its associated oncogenic 
potential has only rarely been considered. 
An exception to the common presumption that EBV lytic-cycle genes do not contribute 
to latency came with the realization that a subset of these genes are expressed for a 
limited period immediately following infection, and which are required for efficient 
immortalization of primary B cells by EBV in vitro, a hallmark property of latent EBV 
infection. These include those encoding the viral BCL-2-related pro-survival proteins 
BHRF1 (vBCL-2) and BALF1 (6), and BZLF1 (also known as Zta) (7, 8). Interestingly, 
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BZLF1, an AP-1-related transcription factor responsible for initiation of the EBV lytic cycle 
upon reactivation of its expression from latent infection, performs a different function upon 
de novo infection: that of promoting cellular proliferation (8). In what appears to be 
consistent with this, SCID mice injected with B cells immortalized by BZLF1- EBV and 
humanized mice infected with BZLF1- virus are less prone to lymphoproliferative disease 
and lymphoma development, respectively, than upon receiving BZLF1+ cells or virus (9, 
10). The EBV BCRF1 gene, which encodes an IL-10 homolog (vIL-10) (11), is also 
expressed early upon infection (12-14), and although there is conflicting evidence for a 
direct role of this protein in B-cell immortalization in vitro (12, 15, 16), it almost certainly 
contributes to latency in vivo through down-regulation of the early immune response to 
newly infected B cells (13, 14), as does a second early-expressed lytic-cycle immune-
modulatory protein, BNLF2a (13). Because expression of these lytic-cycle proteins is 
short-lived, their contributions are believed to be restricted to this pre-latency period, i.e., 
an establishment phase of latency prior to the exclusive expression of the classically 
defined latency genes in the majority of infected B cells (17). 
Whether additional lytic-cycle genes have dual or even distinct roles during latency 
and virus replication is unclear. One such candidate is BHLF1, an early lytic-cycle gene 
for which there is mounting evidence of expression during latency as well. BHLF1 abuts 
oriLytLeft, one of two origins of DNA replication present within the EBV genome that are 
active only during the lytic cycle (a distinct origin of DNA replication, oriP, functions during 
latency). BHLF1 encodes a 2.5-kb unspliced, polyadenylated RNA that is highly 
expressed upon induction of the lytic cycle within latently infected B-cell lines (18-22), and 
early DNA sequencing revealed a long open reading frame (ORF) that is within the 
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transcribed region of the gene (18, 23). Interestingly, an apparent paralog of BHLF1 
exists, LF3, that is adjacent to the second lytic-cycle origin of DNA replication (oriLytRight) 
(18, 24) (Fig. 1). BHLF1 transcripts are also detectable within latently infected B-cell lines 
and tumors by a variety of techniques (25-29), though this is not inconsistent with sporadic 
reactivation of the virus replication cycle in a subpopulation of cells. Several observations, 
however, have provided more direct evidence of latency-associated expression of 
BHLF1. The first was the detection of BHLF1 transcripts upon infection of primary B cells 
in the presence of cycloheximide (30), which, along with a recent RNA-sequencing (RNA-
seq)-based analysis of EBV transcription through the first two weeks post infection, 
supports transcription of BHLF1 at least during the pre-latency phase (31). The second 
was the identification of putative latency-specific transcription initiation sites shortly 
upstream of the BHLF1 start site that is used upon induction of the lytic cycle (32). 
BHLF1 is remarkable in that 61% of the RNA-coding portion and 78% of the ORF is 
comprised of ~12.3 copies of a 125-bp direct repeat that make up the internal repeat 2 
(IR2) domain, alternatively known as the NotI repeats because each repeat contains a 
single NotI restriction site (18, 33, 34). Furthermore, its ORF has an unusually high G/C 
content of 82% (79% within the RNA-encoding portion of the gene), that would contribute 
to a high percentage of Pro (21%) and Gly (15%) in the polypeptide it is predicted to 
encode (as well as 14% Arg and 16% Ala) (18). By contrast, the average G/C content of 
the EBV genome is 57% (23). These properties of the gene early-on raised the possibility 
that BHLF1’s primary function may not be as a protein-coding gene. Direct evidence 
supporting a non-coding function was ultimately revealed by sequence analyses of the 
genomes of the Akata and Mutu EBV isolates, which revealed BHLF1 ORFs containing 
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either a premature termination codon or the absence of a methionine initiation codon, 
respectively, relative to the ORF of the prototypical strain of EBV, B95.8 (35). Further, 
while BHLF1 transcripts in latently infected B-cell lines are readily detected by RNA-seq 
(28, 31, 36, 37), analysis of the EBV transcriptome and proteome in parallel failed to 
detect BHLF1-encoded polypeptides in the same cell population, even upon induction of 
the lytic cycle (38). Collectively, these observations are highly indicative of a non-protein-
coding role for BHLF1, which may function primarily instead via its transcript as a long 
non-coding RNA (lncRNA). This appears to be true in the context of lytic infection, during 
which BHLF1 transcripts contribute to RNA:DNA duplexes at their coding locus to 
promote DNA replication mediated by the adjacent oriLytLeft (39). Recently, additional 
non-coding roles of BHLF1 during productive infection have been implicated by the 
detection of its RNA in virus-induced nodular structures on the periphery of nuclear viral 
replication compartments (40), and the discovery of circular RNAs (circRNAs) expressed 
from this locus upon activation of the lytic cycle (41, 42). There are no clear indications, 
however, of how BHLF1 may contribute directly to EBV latency and long-term 
persistence. 
To address the potential latency function of BHLF1, we generated recombinant EBVs 
(rEBVs) in which either the BHLF1 coding and 5' regulatory region, or the DNA 
corresponding to the ORF alone had been deleted, and monitored viral latency-gene 
expression upon infection of EBV-negative Burkitt lymphoma (BL) cell lines. Following 
infection of BL2 cells, both BHLF1- rEBVs were initially indistinguishable from wild-type 
(WT) rEBV in supporting the latency III (Lat III) program, in which the full complement of 
EBV latency-associated proteins are expressed. Ultimately, however, these BL cells 
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infected with BHLF1- rEBV transitioned to Lat I, defined by exclusive expression of the 
latency genome-maintenance protein, EBNA1, whereas the cells infected with WT rEBV 
sustained Lat III. A second cell line, BL30, likewise supported Lat III initially, but in all 
infections did transition to Lat I; the transition to Lat I, however, was noticeably delayed 
in BHLF1- relative to WT rEBV infections. 
The complete inability to sustain Lat III in BL2 cells could not be attributed to an effect 
of the BHLF1 deletions on adjacent latency-associated genes encoding EBNA2, BHRF1 
or the BHRF1-derived miRNAs. Further, because our rEBVs were derived from the Akata 
isolate of EBV (genome lacks an intact BHLF1 ORF), this contribution of BHLF1 to latency 
is likely through a non-coding mechanism. This interpretation was strengthened by our 
finding that transient expression of BHLF1 protein from an intact ORF required co-
expression of the EBV post-transcriptional regulator protein SM, expression of which is 
exclusive to the lytic cycle. Thus, even among isolates that retain a translatable ORF, 
protein function may be limited to lytic infection. Finally, BHLF1- rEBVs overall were less 
efficient in their immortalization of primary B cells, which unlike EBV-negative BL cells 
require the Lat III program of EBV for growth in vitro. Thus, one way in which BHLF1 may 
contribute to EBV latency is through a non-coding mechanism that favors the Lat III 
program of EBV, which is critical for the establishment of EBV latency and lifelong 




BHLF1 RNA is widely expressed within latently infected B-cell lines. To obtain 
a clearer picture of the range of BHLF1 expression within the different latency programs 
maintained within EBV-infected B cells, we performed RT-qPCR on total RNA from B-cell 
lines that maintain either Lat I or Lat III. Because of the high degree of homology between 
BHLF1 and its paralog LF3, to ensure specific detection of BHLF1 RNA we amplified a 
region unique to BHLF1 that is immediately upstream of the IR2 repeats (Fig. 1) (18). 
Further, to gauge to what degree BHLF1 RNA expression in these cell lines might be 
associated with spontaneous entry into the virus replication cycle, we determined in 
parallel the level of the early lytic-cycle mRNA encoding the EBV protein SM. The SM 
mRNA is abundant within EBV-positive B-cell lines that have been induced to replicate 
EBV (43). SM mRNA or the protein that it encodes have not been found to be expressed 
during latency; thus, detection of its expression is a good indication that at least a 
subpopulation of otherwise latently infected cells have entered the lytic cycle, even if 
abortively so. 
BHLF1 transcripts were readily detected in all latently infected cell lines examined 
(Fig. 2A), regardless of whether the cells maintained Lat I (Kem I, Mutu I and A.21) or Lat 
III (Ak-LCL, Kem III and MH-LCL). As an additional indication of specificity for BHLF1, 
RNA was not detected in the BL line Sal in which the entire BHLF1 locus is deleted from 
its endogenous EBV genomes (44), but was present within MH-LCL cells, which carry the 
B95.8 EBV genome from which LF3 has been deleted (24, 45). As expected, induction of 
the EBV replicative cycle in A.21 BL cells resulted in a substantial increase in BHLF1 and 
SM RNA expression (Fig. 2A). While SM RNA was also detected in all cell lines, the 
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relative level of this lytic-cycle transcript did not always correlate positively with BHLF1 
RNA. For example, and somewhat unexpectedly, Kem III cells exhibited the highest level 
of SM RNA (even higher than in induced A.21 cells), yet BHLF1 RNA levels within Kem 
III were in line with those in cells that expressed relatively low levels of SM RNA, e.g., 
Kem I and MH-LCL. Conversely, MH-LCL expressed one of the higher levels of BHLF1 
transcript (exceeded only by induced A.21 cells), yet expressed one of the lower relative 
levels of SM RNA. In summary of the data presented in Fig. 2A, while in general the 
variation in BHLF1 transcript levels differed only modestly among latently infected B-cell 
lines, it was apparent that there was not always a direct correlation with SM expression. 
We concluded, therefore, that regulation of BHLF1 expression is likely more complex, and 
that the presence of its RNA in a population of otherwise latently infected cells is not 
ostensibly due to a subpopulation of cells that have entered the EBV replication cycle. 
Contributing to this complexity may be the expression of more recently identified 
transcripts originating shortly upstream of the BHLF1 promoter (P1) that directs 
expression of the originally defined 2.5-kb BHLF1 mRNA. These are at least two leftward 
transcripts originating from putative promoters P2 and P3', that were implicated by 
apparent transcription start sites mapped by either RNase-protection assay (P2) or 
localized by RT-PCR (P3') (Fig. 1) (32). Importantly, these RNAs, whose structures have 
yet to be defined, were originally detected within B-cell lines maintaining Lat III, and their 
abundance, unlike that of P1-originating transcripts, was not notably increased upon 
chemical induction of the EBV replicative cycle, i.e., consistent with their expression 
during Lat III (32). To further explore the expression of these transcripts, we performed 
RT-qPCR with primer sets that would detect P3'-derived transcripts alone, or P2 and P3' 
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together (assuming that P3' transcripts overlap the primer-annealing sites within the body 
of the P2 RNAs). Because the amplified portions of the P2 and P3' transcripts are either 
completely (P2) or partially (P3') within the duplicated regions of the EBV genome that 
overlap the BHLF1 and LF3 genes (Fig. 1), to help distinguish between transcripts 
originating from these highly homologous loci, we again included in our analysis RNA 
isolated from the cell lines Sal and MH-LCL. The deletion in the Sal EBV genomes has 
removed the complete BHLF1 locus including P2 and P3' (44), and is thus BHLF1-/LF3+; 
MH-LCL was generated by infection in vitro with the B95.8 isolate of EBV, the genome of 
which lacks 11.5-kbp of DNA due to a deletion that spans the LF3 locus, and is thus 
BHLF1+/LF3- (24, 45). (Note that P3' lies outside of the duplicated domain in BHLF1, 
whereas LF3 P3 lies within its respective duplicated region, i.e., BHLF1 P3' and LF3 P3 
would be distinct promoters (32)). 
As shown in Fig. 2B, transcripts consistent with initiation at P3' or P2 and/or P3' were 
detected in all cell lines tested, but were higher in those that maintained Lat III (MH-LCL 
and Kem III) than in those that maintained Lat I (Kem I and BX1). Although we cannot 
completely exclude the possibility that some of these transcripts originated from LF3, we 
detected little or no transcripts within Sal BL cells (BHLF1-/LF3+). While the previous 
report noted a lack of inducible expression of these transcripts upon activation of the EBV 
lytic cycle within B-cell lines that maintain Lat III (32), we did note an 8- to 14-fold increase 
in their expression upon induction of the lytic cycle in BX1 BL cells, which normally 
maintain Lat I (Fig. 2B, compare BX1 to Induced BX1 results for the respective 
transcripts). This observation may be comparable to the induction of the three latency-
associated LMP genes upon activation of the lytic cycle in Lat I BL lines, which do not 
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express LMPs 1, 2A or 2B during latent infection (5). The 60-fold induction in BX1 cells 
of transcripts amplified with a primer set specific for the unique region of BHLF1 
(immediately upstream of the IR2 domain) would represent the previously characterized 
lytic-cycle BHLF1 transcript, in addition to P2 and/or P3' transcripts, assuming that these 
extend through this BHLF1-unique domain that was targeted for amplification. 
Interestingly, in the experiments represented in Fig. 2B, we detected relatively little 
transcript in Kem III cells with the primer set specific for the unique-region domain; by 
contrast, transcripts could be readily amplified from the same Kem III RNA with the P3 
and P2/P3' primer sets, possibly indicating that Lat III-specific transcripts expressed from 
P2 and P3' are not entirely co-linear with those from the lytic-cycle-specific P1. In 
summary, our results indicated that the BHLF1 locus is transcribed to varying degrees in 
all latently infected B-cell lines examined, but that the expression of transcripts putatively 
originating from the promoters P2 and/or P3′ may be Lat III-specific (their expression in 
Lat I-maintaining B cell lines had not been examined previously (32)). Moreover, the 
structures of these RNAs are likely to be more complex than the originally defined linear 
BHLF1 transcript. 
BHLF1 protein expression is enhanced by SM. In determining a role for BHLF1 
in EBV latency, we considered a potential contribution by the protein that it has been 
reported to encode (46, 47). As a BHLF1-specific antibody was not available, we cloned 
the BHLF1 ORF from the genome of the prototypic EBV strain, B95.8, with a FLAG 
epitope-encoding tag at its 5' end into a eukaryotic expression vector. Upon transfection 
of EBV-negative BL cells with this vector, however, we repeatedly detected little or no 
FLAG-BHLF1 by immunoblotting, even though in our experience the SV40 promoter in 
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this vector (pSG5; Stratagene) is very active in EBV-negative BL cell lines. Because the 
EBV SM protein enhances the expression of a number of EBV replicative-cycle mRNAs 
through several posttranscriptional mechanisms (48, 49), we tested whether SM might be 
required for BHLF1 protein expression. As shown in Fig. 3, notable expression of FLAG-
BHLF1 was only achieved by co-transfection with an SM expression vector, and in a dose-
dependent manner, suggesting that efficient expression of BHLF1 protein is SM-
dependent, and thus would be limited to the EBV replication cycle. 
To test this in the context of virus infection, we originally sought to engineer a rEBV 
that would encode a FLAG-BHLF1. During the generation of this rEBV on an Akata-EBV 
genetic background, we discovered a single-base deletion (relative to the B95.8 EBV 
genome) 57 nucleotides after the start of the ORF, shifting the translational reading frame 
and resulting in a termination codon after an additional 16 nucleotides. Concurrent with 
our unpublished finding, Flemington and colleagues reported the whole-genome 
nucleotide sequences for the Akata and Mutu EBV isolates, revealing the identical single-
base change in the Akata BHLF1 ORF, and the absence of a likely ORF in the BHLF1 
locus as well within the Mutu EBV genome (35). Taken together, these observations and 
the data in Fig. 3 suggested that during latency BHLF1 transcripts may function as 
lncRNAs, and are only able to function efficiently as mRNAs for BHLF1 protein expression 
upon activation of the EBV replication cycle (and SM expression), but only from the 
genomes of EBV isolates for which the BHLF1 ORF has been conserved. 
BHLF1 supports Lat III in established B-cell lines. To determine the potential 
contribution of BHLF1 to EBV latency, we infected the EBV-negative BL cell line BL2 with 
either WT rEBV or our previously described mutant rEBV (ΔB-S) in which the entire 
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BHLF1 ORF and 5′ promoter region (including P2 and P3') had been deleted (50). This 
3,264-bp deletion also removes oriLytLeft and extends to the right boundary of the largest 
reported naturally-occurring deletion found in EBV genomes within a subset of BLs and 
the cell lines derived from them that maintain Wp-restricted latency (44) (Fig. 1). Six 
independently-derived cell lines infected with either WT or ΔB-S rEBV were analyzed for 
latency-associated gene expression upon outgrowth in the presence of G418, resistance 
to which is encoded within these BAC-derived rEBVs. As shown in Fig. 4A (left panel), 
we observed the establishment of Lat III in all WT and ΔB-S rEBV infections, as indicated 
by the detection of EBNA1, EBNA2, the three EBNA3 proteins (3A, 3B and 3C) and LMP1 
through at least 30 days post infection (p.i.). However, by ~2 months p.i., lines infected 
with ΔB-S rEBV appeared to have all transitioned to a Lat I program, as suggested by the 
detection of EBNA1 only (Fig. 4A, right panel). 
To determine whether this was likely to be a bona fide Lat III to Lat I transition, we 
assessed whether EBNA1 promoter usage had indeed shifted from Cp/Wp (Lat III) to Qp 
(Lat I) in the ΔB-S rEBV infections. As shown in Fig. 4B, RT-PCR analysis of EBNA1 
mRNA structure revealed a gradual transition from Cp/Wp- to Qp-driven expression of 
the EBNA1 mRNAs in the ΔB-S infections, whereas Cp/Wp usage was sustained in the 
WT rEBV infections (the primers used do not distinguish between a Cp or Wp origin of 
these transcripts). Consistent with the apparent silencing of Cp/Wp in the ΔB-S infections, 
the levels of EBNA2 and EBNA3C mRNAs (which originate only from Cp or Wp) also 
decreased (Fig. 4C), though these Cp/Wp-specific transcripts remained detectable when 
their encoded proteins were not, most likely due to a greater sensitivity of RT-PCR over 
immunoblotting for the assessment of EBNA gene expression. We also confirmed that 
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the BHLF1 P2/P3' locus was indeed transcribed in BL2 cells infected with WT rEBV, and 
that the inability to amplify these transcripts upon infection with ΔB-S rEBV supports the 
conclusion that these transcripts in the WT rEBV infections originated from the BHLF1 
locus, not from the highly homologous LF3 (Fig. 5). Based on these data, we concluded 
that the deletion in the ΔB-S rEBV genome precluded long-term maintenance of Lat III, 
ultimately resulting in an apparent shift to the Lat I transcriptional program. 
While the results presented in Fig. 4 implicated a role for the BHLF1 locus in the 
maintenance of Lat III, the deletion in ΔB-S rEBV also removed DNA encoding the EBV 
miRNA miR-BHRF1-1, one of three miRNAs encoded within the BHRF1 locus upstream 
of BHLF1 in the opposite transcriptional orientation and that are expressed during Lat III 
(51, 52). Though the phenotypes associated with targeted mutation of the three BHRF1 
miRNAs (either together or individually) in the context of Lat III in primary B lymphocytes 
did not appear to be consistent with an inability to sustain Lat III gene expression (53-55), 
we nonetheless sought to exclude the possibility that loss of miR-BHRF1-1 expression 
contributed to the inability of BL2 cells to sustain Lat III. We therefore generated a second 
mutant rEBV, ΔBHLF1, in which only the DNA corresponding to the BHLF1 ORF (as in 
B95.8-like isolates) was deleted (Fig. 1). The BL2 infection experiments described above 
were then repeated with WT and ΔBHLF1 rEBV, and the results are shown in Fig. 6. In 
all cases, BL2 lines infected with WT rEBV sustained Lat III as observed previously (data 
not shown), whereas those infected with ΔBHLF1 ultimately transitioned to Lat I as had 
the lines infected with ΔB-S rEBV. This was evident at both the protein and mRNA levels 
(Figs. 6A and 6B, respectively), though overall in multiple experiments it seemed that the 
cells infected with ΔBHLF1 did take slightly longer to complete the transition to Lat I than 
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was observed for the ΔB-S rEBV infections. Finally, we also considered whether the 
transition to Lat I may have occurred due to silencing of the EBV genome as a 
consequence of integration of the BHLF1- genomes in EBV-negative BL cells (56). 
However, we were readily able to rescue episomal copies of the EBV genome into E. coli 
from Hirt extracts of these infected BL2 lines, and the amount of rescued episomes 
corresponded well to the total EBV DNA copy number (data not shown), arguing against 
integration of a substantial fraction of viral genomes.  
We next repeated our analysis of both BHLF1- rEBVs within the context of a second 
EBV-negative BL line, BL30. While every infection of BL2 cells with WT rEBV resulted in 
sustained Lat III, this was less pronounced upon infection of BL30 cells. As revealed by 
RT-PCR analysis of Cp/Wp usage in BL30 cells at 1 and 3 months p.i., two of the six 
infections with WT rEBV (nos. 2 and 6) appeared to transition to Lat I by 3 months p.i. 
(Fig. 7A, top). While we observed notable Cp/Wp usage at 3 months p.i. in the remaining 
four infections with WT rEBV, all WT rEBV infections ultimately transitioned to Lat I (data 
not shown). By contrast, upon infection with either BHLF1- rEBV the transition to Lat I was 
more pronounced by 3 months p.i. (Fig. 7A, compare ΔBHLF1 and ΔB-S to WT). The 
generally delayed conversion to Lat I in BL30 cells infected with WT relative to BHLF1- 
rEBV was more pronounced upon reduction of PCR cycles, as shown by the results for 
three representative BL30 lines for each infection (Fig. 7B). (Accurate analysis of Cp/Wp 
usage by RT-qPCR is difficult due to the presence of submolar cDNA products 
representing alternative splicing events and with more than one copy of the W1-W2 exon 
repeat unit of the EBNA mRNAs spanning the large internal repeat [IR1] domain). 
Analysis by RT-qPCR of Qp usage in each infection revealed an increase in Lat I EBNA1 
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expression over 3 months p.i. (Fig. 7C), consistent with reduced Cp/Wp usage over the 
same timeframe. For reasons that are not clear, the amount of Qp-specific transcripts in 
the ΔB-S infections were approximately ten-fold those within the WT and ΔBHLF1 
infections, and generally were equal to or greater than the level of Qp-derived EBNA1 
transcript in the Lat I positive-control line, Kem I. In summary, while BL30 cells infected 
with WT rEBV ultimately supported the transition to Lat I, unlike BL2 cells, deletion of the 
BHLF1 locus appeared to accelerate this process. We concluded, therefore, that BHLF1 
supports Lat III, but the degree to which it does this is cell specific. 
Deletion of the BHLF1 locus has minimal influence on BHRF1 mRNA and 
miRNA expression. The deletions introduced to generate ΔB-S and ΔBHLF1 rEBVs 
were within ~550 bp of the 3' end of the EBNA2 mRNA to their left, and within ~1,800 and 
~530 bp of the BHRF1 3' coding exon and ORF to the right. Also, as noted above, ΔB-S 
completely removes the DNA encoding the EBV miRNA miR-BHRF1-1 within the BHRF1 
locus, whereas the ΔBHLF1 deletion is approximately 1,200 bp upstream of the miR-
BHRF1-1 locus; the remaining BHRF1 miRNAs are derived from the 3' end of the BHRF1 
gene. We did not observe gross differences in EBNA2 expression from either deletion for 
at least 2-4 weeks p.i. (Figs. 4 and 6), arguing against a negative influence on EBNA2 
expression as directly responsible for the transition to Lat I, e.g., due to activation of Qp 
by default in the absence of sufficient EBNA2 to sustain transcription from Cp. We also 
did not observe an effect of these deletions during this timeframe on expression of the 
EBNA3s and EBNA1 whose primary transcripts from Cp/Wp transverse the BHLF1 locus, 
the deletion of which might have interfered with pre-mRNA processing, altering 
expression of their mRNAs. To determine whether the phenotype common to both 
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deletions might have been due to an influence on expression of the adjacent BHRF1 
locus, we measured the levels of the latency-associated BHRF1 mRNAs that encode the 
EBV vBCL-2, an anti-apoptotic homolog of BCL-2 (57-59). We also assessed expression 
of EBV miRNAs miR-BHRF1-1, miR-BHRF1-2 and miR-BHRF1-3 that are generated from 
transcripts transiting the BHRF1 locus, and which are normally expressed during Lat III 
(51, 52). 
BHRF1 mRNA expression during latency is driven by the EBNA promoter Wp and 
possibly Cp, and consequently, the 5' leader of these BHRF1 mRNAs shares an exonic 
structure with the leaders of the EBNA mRNAs (57-59). These contain multiple copies of 
the two-exon repeat W1-W2, each derived from a copy of IR1/BamHI-W restriction 
fragment; the last W2 exon is typically spliced to the first of three short unique-sequence 
exons (Y1, Y2 and then Y3) encoded within the adjacent BamHI-Y restriction fragment, 
though we have observed that the Y3 exon is rarely included within BHRF1 mRNAs (50). 
The Y2 or Y3 exon is ultimately spliced to the single long 3' exon that contains the entire 
BHRF1 ORF within the BamHI-H fragment (57-59). A separate promoter ~600 bp 
upstream of the BHRF1 ORF (and removed by ΔB-S, but not ΔBHLF1) is used for BHRF1 
transcription during lytic infection (57). 
To measure BHRF1 mRNA levels by RT-qPCR we employed a common reverse 
primer specific for the 3' coding exon, and forward (5') primers specific for either the W2 
or Y2 exon. The results for each of six independently-derived BL2 lines infected with either 
WT, ΔB-S or ΔBHLF1 rEBV are shown in Fig. 8. In WT rEBV infections, when employing 
a W2-specific forward primer, the level of BHRF1 mRNA in all BL2 lines was equivalent 
(on average less than two-fold greater) to BHRF1 mRNA levels in the reference cell line 
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Ak-LCL. When using the Y2-specific primer, the levels observed for BHRF1 mRNAs in 
these same WT rEBV-infected BL2 lines ranged from one-half to equivalent to the levels 
observed for Ak-LCL. In the BL2 lines infected with ΔB-S rEBV, levels of BHRF1 mRNA 
were approximately two-fold higher than in their WT rEBV-infected counterparts when 
assessing with a W2-specific primer, and three-fold higher than WT when using the Y2 
primer. In the ΔBHLF1 rEBV infections, BHRF1 mRNAs were only marginally higher than 
in the WT control infections, regardless of the forward primer used. Thus, although the 
increased levels of BHRF1 mRNA associated with either deletion were minimal, we did 
note that the larger deletion (ΔB-S) was associated with a greater increase in expression. 
This was not totally unexpected, as previous work demonstrated that the large deletions 
that remove all of the EBNA2 and most or all of the BHLF1 loci in the EBV genomes within 
the so-called Wp-restricted BL lines are associated with increased BHRF1 expression 
(59, 60), as shown here for the BHRF1 mRNAs amplified with the W2-specific primer from 
RNA isolated from the Wp-restricted BL line Sal. Given the pro-survival function of the 
BHRF1 protein and that neither of the BHLF1 deletions resulted in a decrease in BHRF1 
mRNA expression over several weeks p.i., we considered it unlikely that a reduced ability 
to support Lat III was a direct consequence of any change in BHRF1 expression. 
We next addressed whether our BHLF1 deletions had perturbed expression of miR-
BHRF1-1, miR-BHRF1-2 or miR-BHRF1-3. As shown in Fig. 9, we observed variable but 
generally only minor differences in expression of any of the BHRF1 miRNAs between 
infections with WT compared to ΔB-S and ΔBHLF1 rEBV infections. The exception was 
the expected absence of miR-BHRF1-1 in BL2 cells infected with the ΔB-S virus and 
within the reference line Sal (a Wp-restricted BL line), in which the introduced deletion in 
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ΔB-S and the naturally-occurring deletion in the Sal EBV genome extend through the 
coding region for miR-BHRF1-1. Thus, we concluded that the observed inability to sustain 
Lat III in BL2 cells was a direct consequence of the loss of the BHLF1 locus and a specific 
function that it performs. 
BHLF1 contributes to EBV immortalization and growth of primary B 
lymphocytes. Lat III is critical to the initial stage of EBV infection of B lymphocytes that 
leads to lifelong EBV persistence within B cells of its human host, and is also required for 
sustained growth (immortalization) of primary B cells upon EBV infection in vitro, a 
hallmark property of EBV linked to its oncogenic potential. Given the defect or inefficiency 
in maintaining Lat III that was exhibited by our two BHLF1- viruses in BL2 and BL30 cells, 
which do not require EBV for sustained growth in vitro, and the relatively late 
manifestation of this effect in BL2 cells, we asked whether this would translate to an 
inability of BHLF1- EBV to immortalize primary B cells. Purified B cells from four healthy 
adult donors were therefore infected with WT, ΔB-S or ΔBHLF1 rEBV, and B-cell growth-
transformation/immortalization was scored at six weeks p.i. (due to a limiting number of 
B cells, only those from donors 1 and 4 were infected with both BHLF1- rEBVs). As 
illustrated in Fig. 10, in a total of five independent experiments (B cells from donor 1 were 
assessed twice), 100% transformation was achieved by WT rEBV infection of B cells from 
all four donors at MOIs of ~0.8-1.3 x 10-2. By contrast, for donor 1 B cells, ΔB-S rEBV was 
unable to immortalize B cells over the range of MOIs tested, whereas we did observe 
inefficient transformation by ΔBHLF1 rEBV, i.e., >10-fold lower than by WT rEBV. 
Similarly, ΔBHLF1 rEBV was clearly deficient relative to WT rEBV in the transformation 
of B cells from donors 3 and 4. For reasons that are unclear, transformations of donor 3 
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and 4 B cells by ΔBHLF1 and ΔB-S rEBV, respectively, occurred only in wells at the mid-
range of MOIs tested. Finally, unlike for donors 1, 3 and 4, we did not observe a difference 
between WT and ΔBHLF1 rEBV in growth-transformation of B cells from donor 2, though 
we did note that B cells from this donor appeared to be slightly (~2-3X) more sensitive to 
transformation by WT rEBV than B cells from donors 1, 3 and 4. 
Given the variable requirement for BHLF1 in our immortalization assays, we 
expanded B cells from donor 3 that had scored positive for immortalization following 
infection with either WT or ΔBHLF1 rEBV, and performed a comparative analysis of their 
growth properties. Interestingly, LCLs could not be as easily established from ΔBHLF1 
rEBV-infected B cells as from those infected with WT rEBV. Of eleven ΔBHLF1 lines that 
were established, two were found by PCR to contain BHLF1 DNA, presumably due to the 
outgrowth of B cells containing the donor’s endogenous EBV (note that this did not explain 
the transformation by ΔBHLF1 rEBV observed only in infections at mid-range MOIs). An 
analysis of EBV EBNA and LMP expression in the nine ΔBHLF1 lines by immunoblotting 
(as in Figs. 4 and 6) did not reveal any gross differences relative to LCLs transformed 
with WT rEBV (data not shown). To determine whether ΔBHLF1 LCLs had lower growth 
potentials, several lines each of WT and ΔBHLF1 rEBV-infected B cells were seeded at 
moderately low density (105 cells per ml), and viable-cell concentration was monitored 
daily. As shown by the representative growth curves in Fig. 11 top, LCLs infected with 
WT rEBV exhibited virtually identical growth rates, with each line going through ~4.5 
doublings to reach a maximum density of ~1.2 x 106 cells per ml. By contrast, LCLs 
infected with ΔBHLF1 rEBV either did not expand at all (Fig. 11 bottom, cell lines #1 and 
#2), or did so more slowly than their WT rEBV-infected counterparts, going through ~3 
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doublings to reach a slightly lower maximum density of ~1 x 106 cells per ml (Fig. 11 
bottom, cell lines #5 and #6). Consistent with this apparent growth deficiency, cultures of 
ΔBHLF1 LCLs routinely exhibited lower cell viabilities than those infected with WT rEBV. 
These experiments were subsequently repeated with early-passage LCLs derived 
from the B cells from donor 4, which had also been infected with ΔB-S rEBV (LCLs from 
donors 1 and 2 were unavailable). Interestingly, while we initially observed little difference 
in the growth curves between donor 4 LCLs infected with either WT, ΔBHLF1 or ΔB-S 
virus (4 lines each), each of the LCLs infected with BHLF1- virus subsequently went 
through crisis and were lost, preventing us from performing further analysis on long-term 
LCLs as we had for the BHLF1- LCLs derived from donor 3 (Fig. 11). Collectively, the 
results presented in Figs. 10 and 11, and our difficulty expanding and maintaining LCLs 
infected with either BHLF1- virus, supports our conclusion that the BHLF1 locus 




Originally assigned to the early class of EBV genes (20), BHLF1 has long been 
believed to contribute to EBV biology exclusively within the context of the virus replication 
cycle. Here, we provide evidence of a contribution by the BHLF1 locus to the latent phase 
of EBV infection, which is intimately linked to the oncogenic potential of this herpesvirus. 
Specifically, EBV-negative BL cells (BL2) that upon infection stably support a Lat III 
program of EBV protein expression, were unable to do so after infection with BHLF1- 
virus, instead transitioning to the more restrictive Lat I program. In a BL line that naturally 
transitioned from Lat III to Lat I (BL30), loss of the BHLF1 locus appeared to accelerate 
the transition to Lat I. Seemingly consistent with this, upon infection of primary B cells, 
which unlike BL cells do require the Lat III program for sustained growth in vitro, BHLF1- 
rEBVs exhibited decreased growth-transforming potential relative to WT rEBV. We found 
no evidence that disruption of the BHLF1 locus itself significantly influenced expression 
of adjacent genes that encode proteins or miRNAs during Lat III, thus supporting our 
conclusion that the defects exhibited by our BHLF1- rEBVs are likely to result directly from 
the loss of a latency-related function(s) of the BHLF1 locus. 
While this is the first direct evidence for a role of the BHLF1 locus in latency, from a 
historical perspective it is likely relevant that the naturally occurring deletion (~6.8-8.5 
kbp) that targets BHLF1 within the EBV genomes present in the subset of BL tumors and 
cell lines that maintain so-called Wp-restricted latency (44), was long ago associated with 
a lack of growth-transforming potential of EBV carried by the BL cell line P3HR-1 
(alternatively, P3J-HR-1 or HR-1) (19, 61-64). This deletion variably extends rightward to 
either well within or completely across the BHLF1 locus, and to the left of BHLF1 it 
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removes the entire EBNA2 ORF and a variable portion of the DNA encoding the C-
terminal domain of EBNA-LP (44). Repair or complementation of the deletion within the 
P3HR-1 EBV genome rescues the transforming potential of the virus, and while this 
restoration has been determined to require EBNA2 and to a lesser extent EBNA-LP, a 
requirement for BHLF1 was not assessed (65-68). Later work, seeking to introduce a 
selectable marker into the EBV genome by taking advantage of the efficient 
recombination able to repair the deletion in the P3HR-1 genome, succeeded in inserting 
a 1.8-kbp hygromycin-resistance gene into BHLF1 at a site corresponding to the 44th 
codon of the ORF, and in a transcriptional orientation opposite that of BHLF1 (69). While 
the resulting rEBVs in which BHLF1 had been disrupted in this manner were able to 
transform primary B lymphocytes, the efficiency of transformation was less than 100% 
(range 31% to 100%; mean 65%) (69). These results appear to be consistent with our 
findings here, though for several reasons it is not possible to conclude this with certainty. 
Most notably, only a single inoculum of unknown MOI was used for the transformation 
assays in this earlier study, preventing an accurate comparison to our results in Fig. 10. 
Also, transformation results were not provided for an equivalent inoculum (MOI) of an 
appropriate WT rEBV control, and it was not clear if primary B cells used in the four 
experiments reported were from a single or multiple donors. And finally, it is not known if 
the insertion of the transgene in the opposite transcriptional orientation would have 
actually inhibited a non-coding function of BHLF1. Given our current findings, we consider 
it likely that the complete or partial removal of the BHLF1 locus contributes to the loss of 
EBV transforming potential associated with this naturally occurring deletion. 
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There is increasing evidence that BHLF1 functions via a non-coding mechanism(s), 
possibly through lncRNAs that it encodes. The originally characterized BHLF1 transcript 
is a 2.5-kb unspliced, polyadenylated RNA whose expression is highly induced upon 
activation of the EBV replication cycle (18, 19). Northern blotting analyses in early studies 
revealed little or no detectable presence of the transcript within latently infected B-cell 
lines prior to induction of the lytic cycle, suggesting that transcription of BHLF1 is limited 
to productive infection. Assessment of EBV gene expression upon infection of primary B 
cells in the presence of a protein-synthesis inhibitor, however, indicated the transcription 
of BHLF1 in at least the pre-latency period (30). Consistent with this, a recent RNA-seq 
analysis identified BHLF1 as a member of the first cluster of EBV genes to be transcribed 
upon infection of primary B cells (31). RNA-seq analyses of the EBV transcriptome within 
established BL cell lines that maintain Lat I (28) and B LCLs that support Lat III (36) have 
suggested that BHLF1 transcripts are also present during established latent infections, 
though one could argue that these represent RNAs from highly transcribed BHLF1 loci in 
a minor population of cells that have spontaneously entered the lytic cycle.  
While we found BHLF1 transcripts not to be remarkably abundant in latently infected 
cell lines, their levels also did not always correlate with that of the mRNA encoding the 
early lytic-cycle-specific protein SM (Fig. 2A). Interestingly, in one report mentioned above 
(36) that analyzed EBV transcriptome data from ENCODE RNA-seq results generated 
from EBV-immortalized LCLs, spliced versions of BHLF1 transcripts were identified in 
these Lat III-maintaining B cells. In these transcripts, a novel splice acceptor site within 
the body of the previously characterized BHLF1 mRNA is spliced to at least one of eight 
donor sites ~1.3-97.3 kbp upstream. While the complete structures of these novel BHLF1 
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transcripts could not be deciphered from RNA-seq data, this is potentially significant, as 
all known latency-associated EBV genes (except those encoding the small ncRNAs 
EBER1 and EBER2) encode spliced mRNAs, with all but one (LMP1) containing multiple 
large introns of 3 to upwards of 40 kb. By contrast, only a subset of lytic-cycle mRNAs is 
spliced, and most of these contain 2 or 3 exons separated by short introns of a few- to 
several-hundred bases in length. It should be noted, however, that the number of reads 
specific for these spliced BHLF1 RNAs suggests that they are quite low in abundance 
(36), and indeed we have had difficulty amplifying them by RT-PCR. It now appears, 
however, that these most likely belong to a family of circular RNAs that result from back-
splicing of novel and cryptic splice sites within BHLF1, and which are primarily if not 
exclusively expressed during the lytic cycle of EBV infection (41, 42).  
Several observations collectively provide more definitive evidence of latency-specific 
transcription of BHLF1. Our early analysis of transcription of the EBV genome in a latently 
infected LCL revealed a level of transcription across the BHLF1 locus that was at least 
equivalent to that of the adjacent, latency-specific EBNA2-encoding exon (70); yet by 
northern blotting we did not detect polyadenylated BHLF1 transcripts in the cytoplasmic 
fraction (as would be expected for the highly abundant 2.5-kb BHLF1 mRNA if a small 
percentage of cells had spontaneously entered the lytic cycle). This suggested that 
transcription of BHLF1 can occur during latency, but that a posttranscriptional “block” may 
prevent its expression as an mRNA in the cytoplasm. We find this intriguing in light of our 
current finding (Fig. 3) that efficient expression of protein from an intact BHLF1 ORF may 
require the EBV protein SM, a broadly-acting posttranscriptional regulator of EBV gene 
expression known to affect mRNA stability, processing, export, and translation (48, 49). 
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More recently, analysis of RNA encoded by DNA encompassing oriLytLeft and 
oriLytRight, which abut BHLF1 and its paralog LF3, respectively, implicated the existence 
of novel BHLF1 and LF3 transcription start sites within B-cell lines that maintain Lat III 
(Fig. 1) (32). Notably, these BHLF1 transcription start sites are 360 bp (P2) and ~1 kbp 
(P3') upstream of those used for the 2.5-kb BHLF1 transcript expressed from P1 during 
the lytic cycle (Fig. 1). Further, expression of these novel transcripts did not increase upon 
chemical induction of the lytic cycle in B-cell lines maintaining Lat III, suggesting that 
these RNAs originate from latency-specific promoters (P2 and P3') (32). Our RT-qPCR-
based detection of transcripts originating upstream of the lytic-cycle-specific BHLF1 
promoter P1 (Fig. 2B) is consistent with the existence of such transcripts in the total-RNA 
fraction of latently infected B-cell lines. We also detected expression of these transcripts 
during Lat I, though less so than in B cells maintaining Lat III, consistent with the earlier 
finding that P2/P3'-specific transcripts are less abundant or undetectable in biopsies of 
BL tumors (32), which typically maintain Lat I. Further, although we noted an increase in 
the expression of these transcripts upon the induction of the lytic cycle in BL cells that 
maintain Lat I, the level of induction was modest compared to that seen for the SM gene. 
The structures of these putative latency-specific BHLF1 RNAs have yet to be defined, 
though they appear to be polyadenylated (32). More recent work has indicated that within 
BL cells, albeit those maintaining Lat I, BHLF1 transcripts are predominantly nuclear (71), 
which may explain why these transcripts were not observed by northern blotting in some 
early studies that assessed RNAs from the cytoplasmic fraction of cells. 
The strongest evidence of latency-associated BHLF1 transcription can be gleaned 
from a recent analysis of the cellular transcriptome within individual cells of an EBV-
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immortalized LCL (72). Our examination of these single-cell RNA-seq data for the 
detection of EBV transcripts revealed the presence of BHLF1 RNA in each of ten cells 
whose RNA was profiled (Fig. 12). While some of these BHLF1 transcripts are likely to 
be lytic-cycle specific (suggested by co-detection in some cells of known lytic-cycle 
mRNAs, e.g., the 3′-co-terminal BaRF1, BMRF1 and BMRF2 transcripts (43)), detection 
of BHLF1 transcripts in all cells supports our contention that there is latency-specific  
transcription of this locus. By contrast, the mRNAs of EBNA2 and LMP1, well-established 
latency-associated genes that encode the most abundant EBV latency-associated 
mRNAs during Lat III (70), were only detected in a minority of the cells and at far below 
the number of reads of the BHLF1 transcripts. In this study cDNA synthesis was primed 
with an oligo(dT)-containing oligonucleotide, and BHLF1-specific reads matched to the 
unique-sequence domain immediately upstream of the known BHLF1 polyadenylation 
site. Thus, at least a subset of BHLF1 transcripts expressed during latency appear to be 
polyadenylated and 3' co-terminal with the previously characterized 2.5-kb BHLF1 mRNA. 
Given the apparent transcription of BHLF1 during the phases of EBV latency within 
B cells that are assessable in vitro (Lat I and III), and that the Akata EBV genome used 
to generate our WT rEBV lacks an intact BHLF1 ORF (35), we consider it likely that 
BHLF1’s contribution to EBV latency is non-coding in nature, and possibly dependent on 
a lncRNA acting either in trans or cis. With respect to the latter, BHLF1 RNAs have been 
shown to form RNA:DNA duplexes or R-loops at their site of synthesis, which appears to 
contribute to the function of the adjacent oriLytLeft (39). Currently, it is unclear how such 
hybrids might contribute to latency. One could envision, for example, a contribution to 
regulation of histone modifications and effects on local chromatin structure that, in turn, 
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could positively influence EBV transcription over long distances (e.g., from Cp/Wp), 
possibly by influencing looping of the EBV genome. Alternatively, an effect may not be 
specifically dependent on the lncRNA, but simply the maintenance of active transcription 
through this locus, i.e., features of the lncRNA itself may be largely irrelevant. We also 
considered that, as antisense to the EBNA and BHRF1 primary transcripts originating 
upstream, BHLF1 lncRNAs might regulate rate of transcription or mRNA processing 
through duplex formation with either DNA or RNA. However, we did not observe a notable 
increase or decrease in any of the EBNA mRNAs or proteins (i.e., prior to the apparent 
transition to Lat I) as a consequence of deleting BHLF1. While we did note a small 
increase in the levels of BHRF1 mRNAs (Fig. 8), it is difficult to rationalize how a small 
increase in mRNAs encoding the pro-survival BHRF1/vBCL-2 protein would negatively 
impact maintenance of Lat III and the transforming efficiency of BHLF1- virus. 
Many lncRNAs act in trans, and do so through a variety of mechanisms that involve 
the interaction with regulatory proteins, often existing in a multi-protein:RNA complex 
(reviewed in (73)). Because RNA-binding proteins frequently recognize RNA structure 
rather than solely a specific nucleotide-sequence motif, we find it potentially noteworthy 
that in silico prediction of secondary structure within BHLF1 transcripts reveals these 
RNAs to be highly structured (our unpublished observation). This is particularly evident 
within the IR2 domain that is comprised of ~12.3 copies of the 125-nucleotide NotI repeat, 
and which accounts for ~60% of the length of the unspliced 2.5-kb BHLF1 transcript 
originating from P1 (Fig. 1). Though the actual secondary structure of these RNAs is not 
known, given the largely repetitive nature of BHLF1 transcripts spanning IR2, an attractive 
hypothesis is that repeating stem-loop structures within the repeat domain serve as 
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protein-binding sites that, collectively, could act as a sink for an RNA-binding protein(s) 
to sequester them or otherwise block their normal activity, or possibly serve as a scaffold 
for the assembly of a functional protein complex. Along these lines, in addition to its 
presumed role in the function of oriLytLeft (39), Park and Miller (40) recently identified the 
2.5-kb BHLF1 lncRNA as a component of novel virus-induced nodular structures 
(VINORCs) associated with viral replication compartments and that they propose may 
function to facilitate selective processing and export of viral mRNAs. However, the 
absence of BHLF1-containing VINORCs prior to activation of the lytic cycle (40) argues 
against such a role of this lncRNA during latency.   
Our attempts to rescue the defect of BHLF1- rEBV in BL2 cells by expression of 
BHLF1 in trans have been unsuccessful. Alternatively, any lncRNA may be acting in cis, 
and/or the BHLF1 DNA locus itself may be the critical contributing factor to its apparent 
influence on Lat III and B-cell growth. It is also possible that latency-specific lncRNAs 
expressed from this locus differ in structure and thus function from those of the 
characterized 2.5-kb lytic-cycle RNA encoded by BHLF1, which at best would appear to 
be expressed at a very low level during latency. Of particular note in this respect are the 
transcripts initiating from the putative promoters P2 and P3' (Fig. 1) that we found to be 
more abundant within cells maintaining Lat III than Lat I (Fig. 2B), which correlates with 
our observed positive influence of BHLF1 on Lat III. In addition to these RNAs, an 
apparent family of transcripts antisense to BHLF1 between P1 and P2 were previously 
reported that also appear to be latency-associated (32); it is not clear whether these may 
represent long unspliced versions of BHRF1 mRNAs reported to originate from the same 
region, i.e., within oriLytLeft (58). Moreover, recent mappings of mature 5′ and 3′ termini of 
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EBV transcripts identified clusters of previously unknown transcription initiation and 
polyadenylation sites located ~200-500 and ~500-800 bp downstream, respectively, of 
the major transcription start site for the 2.5-kb BHLF1 transcript, though these also appear 
to be used exclusively upon activation of the lytic cycle within latently infected cells (74, 
75). Given the extensive complexity of transcription within and through the BHLF1 locus, 
clearly an important objective moving forward will be elucidation of the structures of all 
BHLF1 transcripts, as this knowledge will be important to determine the range of RNA 
expression and subcellular location during the different latency programs, and ultimately 
the mechanism of action of the transcripts and whether they indeed contribute to the 
functions regulated by the BHLF1 locus. 
Regardless of whether BHLF1 acts through a lncRNA, our observations suggest that 
it contributes to maintenance of Lat III in EBV-negative BL cells, and such a function is 
not inconsistent with the diminished growth-transforming properties of BHLF1- rEBV. It is 
notable that the apparent inability to sustain Lat III in BL2 cells infected with BHLF1- 
viruses was consistently observed between 1 and 2 months p.i. This delay in a 
measurable phenotype is not inconsistent with a selection against cells that support Lat 
III in the absence of BHLF1, resulting in eventual outgrowth of cells able to transition to 
Lat I by default. Mechanistically speaking, therefore, BHLF1’s role may be an indirect or 
supportive one, rather than as a direct regulator of the Lat III program. This interpretation 
is also not inconsistent with the less than complete requirement for BHLF1 for the 
immortalization of B cells (which to some extent appeared to be donor dependent) and 
the generally poorer growth properties of LCLs that did result from infection with BHLF1- 
rEBV. Thus, upon infection, the net activity or level of a BHLF1 target that must be 
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optimally regulated to promote Lat III may dictate the degree to which BHLF1 is required. 
In other words, BHLF1 may have evolved to fine-tune a specific molecular process to 
ensure efficient establishment of latency, rather than to directly regulate latency-gene 
expression itself. Further, the apparent absolute requirement for BHLF1 to sustain Lat III 
in BL2 cells but not within BL30 cells, an EBV-negative BL line that naturally favored 
transition to Lat I, perhaps should not be surprising given qualitative differences in 
mutational load between endemic (EBV-positive) and sporadic (EBV-negative) BL, and 
among EBV-negative BLs themselves (76). For example, due to mutations distinct from 
those in BL2 cells, BL30 cells may have a greater propensity to epigenetically silence the 
EBV genome, overriding any positive effect of BHLF1 on Lat III as revealed in BL2 cells. 
In conclusion, we have shown that deletion of the BHLF1 locus of the EBV genome 
results in a diminished ability of the virus to immortalize B cells in vitro, a hallmark property 
of EBV latency and one intimately associated with successful colonization by EBV of its 
human host, as well as its significant oncogenic potential. While the mechanism through 
which BHLF1 functions during latency is currently unclear, our results suggest that the 
diminished growth-transforming potential of BHLF1- EBV may be due to an inability to 
fully support the Lat III program of EBV infection that is critical during the establishment 
of a B-cell reservoir of EBV in vivo, and which is required for continued growth of primary 
B cells in vitro. Our results are consistent with increasing evidence over the past decade 
and earlier of latency-associated expression of BHLF1, which has heretofore been 
thought to contribute exclusively to the productive phase of EBV infection. Additionally, 
the lack of conservation of the ORF within BHLF1 among some EBV isolates has raised 
the likelihood that BHLF1 functions not through a protein that it encodes, but either a 
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lncRNA that acts in trans or cis, or an inherent property of the DNA within the locus itself 
that may be regulated by its active transcription. Our results also suggest that in those 
isolates that have retained the BHLF1 ORF, the protein that it encodes may require the 
presence of the EBV posttranscriptional regulator SM for efficient expression, thus limiting 
a protein-coding role to productive infection. And finally, our evidence supporting a 
latency-related function of BHLF1 raises the question of what the contribution may be of 
its paralog LF3, for which latency-associated expression and a non-coding function have 
also been implicated (28, 35).  
34 
 
MATERIALS AND METHODS 
Cell lines. Akata clone 21 (A.21), Kem I, Mutu I and BX1 are BL-derived cell lines that 
support the EBV Lat I program. A.21 was originally cloned from the parental Akata BL line 
(77). BX1 (gift of L. Hutt-Fletcher) was generated by infection of an EBV-negative clone 
of Akata cells with a rEBV (BLX/Rc-TK) in which an expression cassette encoding G418 
resistance and GFP had been inserted into the BXLF1 (thymidine kinase) ORF within the 
genome of the Akata isolate of EBV (78). B-cell lines used in this study that support the 
EBV Lat III program were the BL-derived cell lines Kem III and Raji, and the LCLs Ak-
LCL and MH-LCL generated by immortalization of primary human B lymphocytes in vitro 
with either rEBV derived from Ak-GFP-BAC (see below) or the B95.8 isolate of EBV, 
respectively. Note that while the Kem III line was originally believed to be of BL origin, it 
has recently come to our attention that some Kem III lines may instead be a spontaneous 
B LCL that arose during the primary culture of Kem BL tumor cells. Sal is a BL cell line 
that maintains a Wp-restricted program of EBV latency-gene expression, and contains a 
deletion in its endogenous EBV genomes that has removed the adjacent EBNA2 and 
BHLF1 loci, and the C-terminal coding region of EBNA-LP upstream of EBNA2 (44). BL2, 
BL30 and Louckes are EBV-negative BL cell lines, as is the A.2 clone of the Akata BL 
line. All B-cell lines indicated above were maintained in RPMI 1640 medium (HyClone) 
supplemented with 2 mM L-glutamine (HyClone) and 10% fetal bovine serum (FBS; 
HyClone). Primary B lymphocytes infected in vitro, and the LCLs that resulted from these 
infections (see below) were maintained in RPMI 1640 medium supplemented with 2 mM 
L-glutamine, 15% FBS, and 50 μg gentamicin sulfate per ml (Lonza). The human 
embryonic kidney cell line HEK293 was maintained in Dulbecco’s modified Eagle medium 
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(DMEM; Lonza) supplemented with 10% FBS, except as noted below for production of 
rEBV. All cell lines were maintained at 37°C in a humidified 5% CO2 atmosphere. For the 
induction of the EBV replication cycle, A.21 or BX1 cells were plated in 6-well plates at a 
density of 3 × 106 cells per well, and surface IgG was crosslinked with goat F(ab′)2 
fragment to human IgG (Cappel, MP Biomedicals) added to a concentration of 100 μg per 
ml; cells were harvested for subsequent analysis 48 h after addition of F(ab′)2. 
Immunoblot analysis. For detection of proteins by immunoblotting, cells were 
harvested by centrifugation, washed once with phosphate-buffered saline (PBS), and 
then lysed at 106 cells per 80 μl 2X SDS-PAGE buffer containing 5% β-mercaptoethanol. 
Samples were then sonicated, boiled for 5 minutes, and proteins resolved by SDS-PAGE, 
after which they were subjected to semi-dry transfer onto a PVDF membrane. Cellular 
and EBV proteins were detected by standard immunoblotting techniques using the 
following primary antibodies to: EBNA1, rabbit antiserum (gift of J. Herring); EBNA2, 
monoclonal antibody (mAb) PE2; LMP1, mAb S12; EBNA 3A, 3B and 3C, sheep 
antiserum to each (Exalpha Biologicals, Inc.); actin, mAb JLA20 (Calbiochem); β-tubulin, 
H-234 (Santa Cruz Biotechnology); and FLAG, mAb M2 (Sigma-Aldrich). The following 
secondary antibodies were used: donkey anti-rabbit for EBNA1 and β-tubulin (GE 
Healthcare UK Limited); anti-mouse for LMP1, actin and FLAG (GE Healthcare UK 
Limited); and rabbit anti-sheep (Chemicon) for EBNA3A, 3B and 3C. Immunoblots were 
developed using either Pierce ECL Western Blotting Substrate (Thermo Fisher Scientific) 
or Immobilon Western Chemiluminescent HRP Substrate (Millipore Sigma). 
Expression of BHLF1 protein. For the transient expression of BHLF1 protein, a 
BHLF1 ORF derived from the B95.8 EBV genome was cloned with a FLAG epitope-
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encoding sequence at its 5' terminus into the expression vector pSG5 (Stratagene). Co-
expression of the EBV SM protein was achieved from the vector pcDNA3-SM (gift of S. 
Swaminathan). A pSG5-derived vector encoding FLAG-tagged insulin-degrading enzyme 
(pSG5-IDE) was used as a positive control for transfection and detection of FLAG by 
immunoblotting. Louckes cells (5 × 106 cells per transfection) were transfected by 
nucleofection with plasmid DNA as indicated (Fig. 3) using an Amaxa Nucleofector with 
Solution V and program G-16 according to the manufacturer’s instructions (Lonza). 
Transfected cells were plated in 6-well plates, and after 48 h incubation were harvested 
for immunoblot analysis. 
Isolation and analysis of RNA. Reverse transcription-PCR (RT-PCR) was used to 
assess the expression level of EBV RNAs. For the analysis of mRNA and lncRNA in Figs. 
2A, 4B, 6B and 7, total cellular RNA was extracted using RNA-Bee (Tel-Test) according 
to the manufacturer’s instructions, followed by digestion with either RQ1-DNase 
(Promega) or TURBO DNase (Thermo Fisher Scientific) to remove residual DNA. The 
cDNA template for PCR was generated from 2 μg total RNA in 19-μl reactions containing 
200 U SuperScript III reverse transcriptase (Invitrogen) according to the manufacturer’s 
instructions, using either 0.1 µM gene-specific primer (GSP) or 2.5 μM random decamers 
(the latter were used for reverse transcription of EBNA1, EBNA2, EBNA3C and GAPDH 
mRNAs); GAPDH mRNA served as an expression reference. A complete description of 
oligonucleotide primers and probes is provided in Table 1, with the exception of GAPDH 
primers and TaqMan™ probe, which were purchased as a kit (Applied Biosystems). 
Corresponding negative-control reactions did not contain reverse transcriptase (-RT). For 
end-point RT-PCR (Figs. 4 and 6), 2 μl of the cDNA synthesis or -RT control reaction was 
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amplified in a 25-μl reaction containing 0.5 μM each PCR primer, 0.25 mM dNTPs, 1X 
PCR buffer without Mg, 1.5 mM MgCl2, and 4 U Platinum Taq DNA polymerase 
(Invitrogen) using the following cycling conditions: 95°C for 3 min; 30-35 cycles of 95°C 
for 15 s, the appropriate annealing temperature (55oC or 60oC) for 30 s, and 72°C for 1 
min; and a final extension at 72°C for 10 min. For quantitative (real-time) analysis of RNA 
levels by RT-qPCR (Figs. 2A and 7), cDNA synthesis was primed as described above 
with GSPs for BHLF1, BHRF1 and SM RNAs (Table 1), or random decamers for GAPDH. 
Quantitative PCR was performed using 2 μl of cDNA template in a 20-μl volume 
containing 1X TaqMan™ Universal Master Mix II (Applied Biosystems), 900 nM each 
primer and 250 nM FAM-labelled TaqMan™ probe. A GAPDH TaqMan™ probe (Applied 
Biosystems) was included as an internal control. Parameters for qPCR were 10 min at 
95oC, followed by 40 cycles of 15 s at 95oC, 60 s at 60oC. Relative gene expression to a 
reference LCL was determined using the comparative Ct method (2−ΔΔCt). 
A slightly different protocol was employed for the quantification of BHLF1 RNA levels 
reported in Figs. 2B and 5. Briefly, total cellular RNA was extracted using the QIAshredder 
and RNeasy® Plus Mini Kit (Qiagen) according to the manufacturer’s instructions, 
digested with TURBO DNase, and then purified according to the RNA cleanup protocol 
of the RNeasy Mini Kit (Qiagen). cDNA was synthesized from 1 µg RNA in a 20-µl reaction 
containing the appropriate GSP (100 nM) and 200 U SuperScript III according to the 
manufacturer’s instructions. As above, -RT controls were run in parallel. The GSPs for 
the P3', P2/P3' and Unique BHLF1 primer sets (Table 1) were either individually 
multiplexed with a GAPDH GSP (instead of random decamers) in the same cDNA 
synthesis reaction (Fig. 2B), or cDNA synthesis was primed with each BHLF1 and 
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GAPDH GSP in a separate reaction (Fig. 5). Singleplex BHLF1 (P3', P2/P3' or Unique 
primer sets) and GAPDH qPCR reactions were performed in triplicate in 20-µl reaction 
mixtures containing 2.0 µl of the cDNA-synthesis (undiluted or diluted eight-fold) or -RT 
control reaction, 1X TaqMan™ Universal Master Mix II, BHLF1 forward and reverse PCR 
primers (each 0.5 µM) or 1X GAPDH TaqMan Assay reagent (Thermo Fisher Scientific), 
and the appropriate TaqMan™ probe (250 nM). The qPCR cycling parameters were 10 
min at 95°C, followed by 45 cycles of 15 s at 95°C, and 60 s at 57oC or 60oC. GAPDH 
reactions were amplified in the same 96-well plate as BHLF1 reactions to ensure 
equivalent amplification conditions. Relative gene expression was determined using the 
comparative Ct method (2−ΔΔCt). 
For the analysis of EBV miRNA levels by RT-qPCR (Fig. 8), RNA was isolated from 
cells using the Ambion mirVana miRNA Isolation Kit (Life Technologies) as directed by 
the manufacturer. RT-qPCR employing 10 ng of RNA was performed using the TaqMan™ 
MicroRNA Reverse Transcription Kit and miRNA assays for EBV miRNAs miR-BHRF1-
1, -2, and -3 (Applied Biosystems) according to the manufacturer’s instructions. 
Amplification of U6 snRNA was used as an internal control, and sample values were 
normalized to an EBV-positive reference cell line. The parameters for qPCR were as 
above with 40 cycles and 60oC for annealing/extension. All RT-qPCR (mRNA, lncRNA 
and miRNA) was done with a StepOnePlus Real-Time PCR System (Applied 
Biosystems).  
Generation of BHLF1- rEBV. Both WT and mutant rEBVs were generated from the 
Akata EBV genome present within the BAC Ak-GFP-BAC (clone 12-15) (79). Two BHLF1- 
rEBVs were employed in these studies, ΔB-S and ΔBHLF1, that contained deletions 
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removing different amounts of the BHLF1 locus (Fig. 1). Generation of ΔB-S rEBV by 
BAC recombineering has been described in detail previously (50). Briefly, a 3.3-kbp 
deletion (ΔB-S) was introduced within Ak-GFP-BAC that corresponded to nucleotide 
coordinates 38,287 to 41,550 of the composite WT EBV genome derived from the B95.8 
and Raji isolates (NC_007605.1). This deletion extends rightward from the stop codon of 
the BHLF1 ORF, to the right boundary of the naturally-occurring 8.5-kbp deletion present 
in the endogenous EBV genomes within the Sal BL line, and thus removes the entire 
BHLF1 ORF (38,287-40,269) and approximately 1.3 kbp of DNA upstream of it that spans 
the transcription start sites for the BHLF1 promoters P1 (40,520), P2 (40,879) and P3' 
(~41,514), as well as oriLytLeft (40,301-41,293) (Fig. 1). The final deletion step in E. coli 
was mediated by flippase recombinase (Flp), and thus a single 34-bp Flp recognition 
target (FRT) element is present at the site of deletion. For the generation of ΔBHLF1 
rEBV, a deletion (ΔBHLF1) was introduced within Ak-GFP-BAC that corresponded to the 
BHLF1 ORF in the B95.8 EBV genome (38,287-40,269). The introduction of ΔBHLF1 was 
accomplished with the galactokinase (galK) positive/negative selection method of 
recombineering in E. coli strain SW105 (80). Briefly, a galK expression cassette flanked 
by 50 bp of DNA homologous to the regions immediately upstream and downstream of 
the BHLF1 ORF was generated by PCR; this DNA fragment was introduced by 
electroporation into SW105 cells carrying Ak-GFP-BAC for the replacement of the BHLF1 
target with galK by homologous recombination. The DNA was isolated from multiple GalK-
positive clones (able to grow on minimal medium agar plates with galactose as the sole 
carbon source), and correct recombination within the BHLF1 locus was confirmed by PCR 
amplification across the galK-EBV DNA junctions followed by sequence analysis of 
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amplified DNA. Next, to remove the galK cassette, SW105 cells carrying Ak-GFP-BAC 
DNA in which the ΔBHLF1 deletion had been appropriately introduced were 
electroporated with a dsDNA oligonucleotide representing the fused 50-bp homology 
arms of EBV that had been used to introduce the galK cassette. GalK-negative clones, 
which would carry ΔBHLF1-Ak-GFP-BAC, were identified by growth on minimal media 
agar containing a glycerol carbon source and 2-deoxy-galactose, which selects against 
bacteria still containing and expressing galK. From these clones, DNA was isolated and 
subjected to amplification and DNA sequence analysis to verify appropriate removal of 
the galK cassette, resulting in ΔBHLF1. Unlike for ΔB-S, the final deletion step was not 
mediated by Flp, thus resulting in a seamless deletion. The Ak-GFP-BAC DNAs with ΔB-
S and ΔBHLF1 deletions were transferred into E. coli DH10B, from which BAC DNA was 
purified with the NucleoBond BAC100 kit (Clontech) and subjected to restriction analysis 
and Southern blot hybridization to ensure against unintended recombination, deletions 
and rearrangements.   
Virus production and infection of BL2 cells. For the production of rEBV, 4 x 105 
HEK293 cells were seeded into each well of a 6-well plate and transfected with 2 µg Ak-
GFP-BAC (WT) or its ΔB-S or ΔBHLF1 derivative using TransIT-293 transfection reagent 
(Mirus), and stable transfectants selected with G418 (Geneticin; 500 μg/ml). Individual 
G418-resistant colonies that were also GFP-positive were selected, expanded and 
assessed for rEBV production. To induce EBV replication, cells were seeded at 6.3 x 106 
cells per 150-mm plate 24 h prior to transient transfection as above with 15.6 μg each of 
expression vectors for the EBV BZLF1 and BALF4 (gB) proteins; at 24 h post-transfection, 
sodium butyrate and 12-O-tetradecanoylphorbol-13-acetate (TPA) were added to the 
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culture medium at final concentrations of 4 mM and 20 ng/ml, respectively. After 3 h, the 
cell monolayers were rinsed and then incubated in fresh RPMI growth medium (instead 
of DMEM) for 4 days, after which the culture medium was clarified by centrifugation and 
passed through a 0.45-μm filter. To select clones that produced the highest amount of 
rEBV, virus titers were determined by conversion of Raji BL cells to GFP expression. 
Briefly, 5 × 105 Raji BL cells in 1 ml were added to each well of a six-well plate, and mixed 
with 1 ml of increasing dilutions of the filtered rEBV-containing HEK293 culture 
supernatant. Plates were then centrifuged at 200 × g for 1 h at 4°C, and then incubated 
at 37oC for 24 h, at which time 2 ml of fresh RPMI 1640 culture medium was added to 
each well. At 3 days p.i. the cells were analyzed for GFP expression by flow cytometry 
using a BD FACSCalibur (BD Biosciences). Flow cytometry data was analyzed using 
FlowJo software and the viral titer expressed as green Raji units (GRU) per ml. For large-
scale production of virus, HEK293 clones producing the highest titer of WT or BHLF1- 
mutant rEBVs were expanded in 150-mm plates and processed as described above to 
induce virus replication. Filtered culture supernatants were then concentrated 
approximately 25- to 45-fold by tangential flow filtration using a MidiKros hollow-fiber filter 
module with a pore rating of 500 kD (Spectrum Labs) and a Bio-Rad Model EP-1 Econo 
Pump at a rate of 10 ml/min. Aliquots of the concentrated virus were frozen and stored at 
-70oC prior to determining the virus titer as above. Virus used in individual experiments 
was never exposed to more than one freeze-thaw cycle. To infect BL2 cells, 5 × 105 cells 
were infected at an MOI no greater than 1 in 6-well plates as described above. At 24 h 
p.i., most of the culture medium was removed and replaced with 3 ml of fresh RPMI 1640 
growth medium and 1 ml conditioned medium taken from cultures of uninfected BL2 cells. 
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At 5 to 7 days p.i. infected cells were placed under G418 selection (Geneticin; 500 μg/ml) 
and subsequently expanded for further analysis. 
Isolation, infection and analysis of primary B lymphocytes. Human CD19+ B 
lymphocytes were isolated from the whole blood of anonymous adult donors. Following 
isolation of the peripheral blood mononuclear cells (PBMCs) by gradient centrifugation on 
Lymphocyte Separation Medium (LSM; MP Biomedicals), B cells were isolated from the 
PBMC fraction by positive selection using human CD19 MicroBeads (Miltenyi Biotec) 
according to the manufacturer’s instructions. Alternatively, purified CD19+ B cells were 
purchased from STEMCELL Technologies. For infection, primary B lymphocytes were 
plated in 96-well plates at 5 × 104 cells per well, WT or mutant rEBV was added at a 
starting MOI of 0.068 and two-fold serial dilutions thereof, and the plates were then 
centrifuged at 1000 rpm for 1 h at 13°C prior to incubation at 37oC. Growth medium was 
replaced weekly, and at 6 weeks p.i. the wells of infected cells were scored for 
transformation, indicated by yellowing of the growth medium, cell clumping, and GFP 
expression. The cells from transformation-positive wells were then expanded to establish 
cell lines for further analysis. To assess growth properties, cells were seeded in triplicate 
in 6-well plates (5 ml per well) at 1 x 105 cells per ml in LCL growth medium containing 
15% FBS. Viable-cell concentration was then determined daily by trypan blue dye-
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Figure 1. Organization of the gene locus for BHLF1 and that of its paralog, LF3. The 
EBV genome (top) is shown in its linear configuration (not to scale) bounded by its 
terminal repeats (TR); major internal direct repeat elements (IR1-IR4) and the origin of 
EBV DNA replication utilized during latency (oriP) are shown for reference, as are the 
common EBNA promoters Cp and Wp, and the EBNA1-only promoter Qp. The BHLF1 
and LF3 genes overlap the two highly homologous origins of EBV DNA replication, 
oriLytLeft and oriLytRight, respectively, active during productive (lytic) infection. In some 
EBV genomes a long ORF (colored arrows) is present within the transcribed regions of 
BHLF1 and LF3 that are composed primarily of related direct repeats (vertical lines) of 
125 (IR2) and 102 (IR4) bp, respectively; copy numbers of IR2 and IR4 repeats may vary 
and are based here on the complete composite EBV genome derived from the B95.8 and 
Raji isolates of EBV (accession number NC_007605.1). The ~1 kbp duplicated-sequence 
domains DSL and DSR that encompass oriLytLeft and oriLytRight, respectively, are 
underscored by the green bar. Solid horizontal arrows depict the previously characterized 
transcripts that are highly expressed from the BHLF1 and LF3 P1 promoters upon 
induction of the EBV replicative cycle, and which are unspliced and polyadenylated at 
sites indicated by short vertical arrows. Transcription start sites upstream of P1 that 
implicate latency-specific promoters have been mapped by nuclease-protection assay 
(P2) or were localized by RT-PCR (P3', P3 and P4) (32). The structures of these 
transcripts have not been defined, and thus are represented here as dashed arrows 3' 
co-terminal with the P1 transcripts from either locus. The ΔBHLF1 and ΔB-S deletions 
within mutant rEBVs used in this study are depicted below the expanded BHLF1 locus.  
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Figure 2. Widespread expression of BHLF1 RNA in latently infected B-cell lines. RT-
qPCR was used with three different primer sets to determine the relative level of BHLF1 
transcripts within B-cell lines that maintain Lat I or III, or in Akata BL-derived Lat I lines 
(A.21 and BX1) that had been treated by cross-linking of surface IgG to induce the EBV 
replication cycle. (A) BHLF1 RNAs (left panel) were amplified with a primer set specific 
for the unique-sequence domain (Unique BHLF1) immediately upstream of the IR2 
repeats within the known BHLF1 mRNA and not present within RNAs encoded by LF3. 
Levels of SM transcripts were determined in parallel (right panel) to provide an indication 
of the degree of EBV lytic-cycle gene transcription supported in each cell line. Level of 
expression shown for both BHLF1 and SM transcripts is relative to that of the respective 
RNA in Ak-LCL cells (Lat III), which was arbitrarily set at 1.0. (B) In addition to the primer 
set used to obtain the BHLF1 results in (A), primer sets expected to detect the putative 
latency-specific transcripts initiating from P2 or P3' (P2/P3') or P3' were used. Because 
these primers target the duplicated sequence elements present in the highly homologous 
BHLF1 and LF3 loci, RNA from MH-LCL cells was used as a reference, since the genome 
of the B95.8 isolate of EBV within this LCL lacks the LF3 locus, a consequence of a 11.5-
kbp deletion. Conversely, the BHLF1 locus is absent from the EBV genomes within the 
Sal BL line, also due to a naturally occurring deletion; consequently, amplification of RNA 
from Sal cells with the P2/P3' and/or P3' primer sets would be indicative of LF3 
transcription. The relative positions of the primer sets employed for reverse transcription 
and qPCR are shown as shaded bars in relation to their position within the various BHLF1 
transcripts (see diagram). Kem I, Mutu I, A.21 and BX1 maintain Lat l; Ak-LCL, Kem III 
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and MH-LCL maintain Lat III. Sal cells support Wp-restricted latency (Lat III, but minus 
expression of EBNA2, LMP1 and LMP2). BL2 and A.2 are EBV-negative BL cell lines. 
Figure 3. BHLF1 protein expression is enhanced by SM. EBV-negative Louckes BL 
cells were co-transfected with an expression vector encoding FLAG-tagged BHLF1 
(origin: B95.8 EBV DNA) and 5 or 10 µg of expression vector for the EBV SM protein, or 
the empty pcDNA3 expression vector. Symbols +, - and the closed triangle indicate the 
presence, absence, or increasing amount of the indicated expression vector, respectively. 
All transfections contained an equal amount of plasmid DNA, adjusted with empty 
expression vector (20 µg total plasmid DNA, lanes 1-3; 10 µg total plasmid DNA, lanes 4 
and 5). Protein expression was detected by immunoblotting for the FLAG epitope (BHLF1 
and insulin degrading enzyme [IDE], a positive control for detection of FLAG), or α-actin 
(gel-loading control). Results are representative of four experiments, each of which 
revealed a dependence on SM for efficient BHLF1 protein expression. 
Figure 4. The BHLF1 locus is required to sustain Lat III. (A) Immunoblot detection 
of EBV latency-associated proteins expressed in BL2 cells at 30 and 68 days post 
infection (dpi) with either WT or ΔB-S rEBV revealed a shift from Lat III to a Lat I-specific 
pattern of EBV protein expression (EBNA1 only) in cells infected with the BHLF1- rEBV. 
All BL2 cell lines (nos. 1-6) resulted from independent infections by the WT or mutant 
rEBV. Detection of α-actin or β-tubulin served as loading controls. (B) Analysis of EBNA1 
promoter usage by endpoint RT-PCR at 28, 41 and 68 dpi revealed a shift from Cp/Wp- 
to Qp-driven EBNA1 mRNA expression (Lat III to Lat I) in BL2 cells infected with ΔB-S 
rEBV, and corresponded to the loss of Lat III-specific protein expression as seen in (A). 
Amplification of EBNA1 cDNAs generated from the RNA of Kem I (Lat I), Kem III (Lat III) 
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and BL2 (EBV-negative) cells served as controls. (C) A similar decrease in EBNA2 and 
EBNA3C mRNA expression was detected in BL2 cells when infected with ΔB-S but not 
with WT rEBV. 
Figure 5. BHLF1 RNA levels within six independently derived BL2 cell lines at 
approximately 1 month p.i. with either WT or ΔB-S rEBV were determined by RT-qPCR 
in triplicate; error bars indicate the standard deviation. Values are relative to the level of 
RNA in MH-LCL (LF3-) determined with primer sets specific for transcripts initiating at P2 
and/or P3' (P3'-initiating transcripts may overlap those from P2), or at P3' alone (see 
diagram, Fig. 2B). RNA from BL2 cells infected with ΔB-S rEBV (BHLF1-, LF3+) was 
included to help exclude the possibility that products amplified with the P2/P3' and P3' 
primer sets had originated from the highly homologous LF3 locus. Comparable results 
were obtained in separate experiments when amplification was done using a primer set 
specific for the unique-sequence domain of BHLF1 (data not shown).  
Figure 6. rEBV lacking the BHLF1 ORF alone is unable to sustain Lat III. EBV 
latency-gene expression was assessed in BL2 cells infected with ΔBHLF1 rEBV at 18-
386 dpi, as described in the legend for Fig. 4. (A) Detection of EBNA and LMP1 
expression by immunoblotting. (B) Detection by endpoint RT-PCR of EBNA1 mRNAs 
from Cp/Wp or Qp, and of EBNA3C mRNA at 18/23, 60 and 92 dpi. The smaller EBNA3C 
cDNA bands detected at 60 and 92 dpi in ΔBHLF1 rEBV-infected cell line no. 2 were 
determined by DNA sequence analysis to be splicing variants of the EBNA3C mRNA. 
BL2 cells infected in parallel with WT rEBV failed to transition to Lat I (data not shown), 
as also observed independently in Fig. 4. 
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Figure 7. BHLF1 contributes to but is not essential for transition to Lat I in BL30 BL 
cells. EBV-negative BL30 cells were infected with either WT, ΔBHLF1 or ΔB-S rEBV, and 
cell lines resulting from six independent infections with each virus were assessed by RT-
PCR for Cp/Wp (Lat III) and Qp (Lat I) usage at 1 and 3 months p.i. (mpi). Results 
indicated that BL30 cells infected with WT rEBV were able to support Lat I, but their 
apparent transition to Lat I was generally delayed relative to cells infected with either 
BHLF1- virus. (A) Detection by endpoint RT-PCR (35 cycles) of Cp/Wp usage for EBNA1 
mRNA expression in six cell lines at 1 and 3 mpi with either WT, ΔBHLF1 or ΔB-S rEBV. 
GAPDH mRNA was amplified in parallel as a control for RNA integrity. Kem I (Lat I), Kem 
III (Lat III) and uninfected BL30 cells served as controls. (B) Cell lines 3, 4 and 5 from 
each infection were reassessed by endpoint RT-PCR at 30 cycles to highlight the 
generally delayed transition (loss of Cp/Wp usage) to Lat I in BL30 cells infected with WT 
rEBV, as in WT lines 4 and 5. The smaller, sub-molar amplification product seen in (A) 
and (B) represents an alternatively-spliced transcript, which complicates assessment by 
RT-qPCR. (C) Quantification by RT-qPCR of Qp usage for EBNA1 mRNA expression 
indicative of Lat I. Data were analyzed by the ΔΔCT method with expression values 
normalized to GAPDH mRNA; the Qp values for Kem I cells (Lat I) were set at 1. Note 
that the expression scale is different in the bottom panel due to higher amounts of Qp-
derived transcripts in BL30 cells infected with ΔB-S rEBV. 
Figure 8. Deletion of the BHLF1 locus does not negatively impact expression of 
BHRF1 mRNA. Expression of the latency-associated BHRF1 mRNA was analyzed by 
RT-qPCR at 1 month p.i. with either: (A) WT versus ΔB-S rEBV; or (B) WT versus 
ΔBHLF1 rEBV. Each of the six WT lines in (A) are distinct from the six WT lines in (B), 
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i.e., a total of twelve independent BL2 lines infected with WT rEBV were analyzed. Each 
bar represents the mean relative level of expression determined, in triplicate, for the 
BHRF1 mRNA in the tested line relative to the respective BHRF1 mRNA level (set at 1.0) 
in the Lat III reference line Ak-LCL. The forward (5') PCR primers used were specific for 
either the W2 or Y2 exon present within EBNA and BHRF1 mRNAs expressed from either 
Cp or Wp. The Wp-restricted BL line Sal was included as an additional reference, as it 
contains a deletion in its endogenous EBV genomes that removed the DNA encoding the 
Y2 exon, rightward through EBNA2 and BHLF1, to the same relative 3' coordinate as the 
deletion within ΔB-S rEBV (consequently, Y2-exon-specific detection of BHRF1 mRNA in 
Sal was negative). Error bars indicate the standard error of the means. 
Figure 9. Deletion of the BHLF1 locus does not impact expression of BHRF1 
miRNAs. Expression of miR-BHRF1-1, miR-BHRF1-2 and miR-BHRF1-3 at 1 month p.i. 
was assessed by RT-qPCR for the same BL2 cells as analyzed for BHRF1 mRNA 
expression in Fig. 8. BL2 cells were infected with: (A) WT or ΔB-S rEBV; or (B) WT or 
ΔBHLF1 rEBV. Each bar represents the mean relative level of expression determined, in 
triplicate, for each of the three BHRF1 miRNAs relative to the respective BHRF1 miRNA 
level (set at 1.0) in the Lat III reference line Ak-LCL. miR-BHRF1-1 is absent in BL2 cells 
infected with ΔB-S rEBV and the BL line Sal due to the introduced or naturally occurring 
deletions in the EBV genomes within these lines, respectively. Error bars indicate the 
standard error of the means. 
Figure 10. BHLF1 contributes to EBV-mediated B-cell immortalization. Primary B 
lymphocytes from four adult donors were infected in vitro with either WT, ΔB-S (donor 1 
and 4 only) or ΔBHLF1 rEBV at the indicated multiplicity of infection (MOI). 
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Immortalization was scored at six weeks p.i. and is presented as percent of wells out of 
eight for each MOI that exhibited outgrowth of cells. The paired WT1 and ΔB-S, and WT2 
and ΔBHLF1 infections of donor 1 B cells were done at different times (cells were frozen 
for later infection with WT and ΔBHLF1 rEBVs). Unlike for B cells from donors 1, 3 and 4, 
donor 2 B cells were equivalently susceptible to immortalization by WT or ΔBHLF1 rEBVs; 
however, donor 2 cells were ~3-4 times more sensitive to immortalization than those of 
the other three donors. 
Figure 11. B lymphocytes immortalized with ΔBHLF1 rEBV exhibit reduced growth 
properties. Shown are representative growth curves of three B LCLs immortalized by WT 
rEBV (top), and four immortalized by infection with ΔBHLF1 rEBV (bottom). All LCLs were 
derived from B-cell donor 3 (Fig. 10). Cells were seeded in triplicate at 1 x 105 cells per 
ml, and the mean viable-cell number per ml of culture medium was determined daily 
afterwards. 
Figure 12. The BHLF1 locus is uniformly transcribed during Lat III. Single-cell RNA-
seq analysis of the EBV transcriptome in ten cells of the B LCL GM12878, immortalized 
by the B95.8 isolate of EBV, indicated that BHLF1 transcripts were present in each cell. 
This was in contrast to heterogeneous detection of transcripts encoded by known latency-
associated genes, e.g., EBNA1, LMP2A/2B, EBNA2 and LMP1 (note that transcripts from 
the latter two genes were not evident in this figure due to the scale used for the vertical 
axis). Other peaks represent various lytic-cycle transcripts. The results shown were 
obtained by analysis, as described (81), of publically available datasets from 
https://www.encodeproject.org/experiments/ENCSR673UIY/  (72). 
 
TABLE 1 RT-PCR primers and TaqMan™ probes for detection of mRNA and lncRNAa 






    
BHLF1-GSPc BHLF1 unique 
region 
TCTGGGGGTCGCTGCAT 39927-39943 Synthesis of BHLF1 
cDNA (Fig. 2) 
BHLF1-Fwdd BHLF1 unique 
region 
GTACGCCTGGATTGCCG 39992-40008 Amplification of BHLF1 
cDNA (Fig. 2) 
BHLF1-Revd BHLF1 unique 
region 
AGGTCGGACTAGCGGATG 40130-40113 Amplification of BHLF1 
cDNA (Fig. 2) 
P2-BHLF1-GSP BHLF1 downstream 
of P2 promoter 
TTAAGGTTTGCTCAGGAGTGG 40557-40577 Synthesis of P2/P3'-
BHLF1 cDNA (Figs. 2, 5) 
P2-BHLF1-Fwd BHLF1 downstream 
of P2 promoter 
GCTTAGGATACCTCCAGGATAATG 40856-40833 Amplification of P2/P3′- 
BHLF1 cDNA (Figs. 2, 5) 
P2-BHLF1-Rev BHLF1 downstream 
of P2 promoter 
CCATAGGGTTGAACCAGGAG 40745-40764 
 
Amplification of P2/P3′- 
BHLF1 cDNA (Figs. 2, 5) 
P3'-BHLF1-GSP BHLF1 downstream 
of P3′ promoter 
TAGAACCTAGAGGAAGGGAACC 41043-41064 Synthesis of P3'-BHLF1 
cDNA (Figs. 2, 5) 
P3'-BHLF1-Fwd BHLF1 downstream 
of P3′ promoter 
GAGCCGTCCTTATTCTTGCT 41468-41449 Amplification of  P3′-
BHLF1 cDNA (Figs. 2, 5) 
P3'-BHLF1-Rev BHLF1 downstream 
of P3′ promoter 
GCCTCACCATGACACACTAA 41333-41352 Amplification of  P3′-
BHLF1 cDNA (Figs. 2, 5) 
SM-GSP SM ACCGCCAGCATCGACTGT 71146-71163 Synthesis of SM cDNA 
(Fig. 2) 
 
SM-Fwd SM GGGCAAGGTGACAAATGTAATC 71211-71232 Amplification of SM 
cDNA (Fig. 2) 
SM-Rev SM AAGAACGCAGCCAGAGG 71302-71286 Amplification of SM 
cDNA (Fig. 2) 
Random decamers N/Ae N/A N/A Synthesis of EBNA1, 
EBNA2, EBNA3C (Figs. 
4, 6) & GAPDH (Fig. 7) 
cDNA 
BHRF1-GSP BHRF1 exon HF TTCTCTTGCTGCTAGCT 42192-42176 Synthesis of BHRF1 
cDNA (Fig. 8) 
W2-Fwd EBNA/BHRF1 Exon 
W2 
TGGTAAGCGGTTCACCTTCAG 14810-14830 Amplification of Cp/Wp-
derived BHRF1 cDNA 
(Fig. 8) 
Y2-Fwd EBNA/BHRF1 Exon 
Y2 
GAGGATGAAGACTAAGTCACAGGCTTA 35680-35706 Amplification of Cp/Wp-
derived EBNA1, EBNA2, 
EBNA3C & BHRF1 
cDNA (Figs. 4, 6-8) 
Qp-Fwd EBNA1 5′ exon Q AAGGCGCGGGATAGC 50137-50151 Amplification of Qp-
derived EBNA1 cDNAs 
(Figs. 4, 6, 7) 
Qp-Rev EBNA1 exon U TCTACTGGCGGTCTATGATGC 55322-55302 Amplification of Qp-
derived EBNA1 cDNA 
(Fig. 7) 
EBNA1-Rev/GSP EBNA1 3′ exon K CTCTATGTCTTGGCCCT 95863-95847 Amplification of Cp/Wp- 
& Qp-derived EBNA1 
cDNA (Figs. 4, 6); 
synthesis of EBNA1 
cDNA (Fig. 7) 
EBNA1-Rev' EBNA1 3' exon K GTACCTGGCCCCTCGTCA 95684-95667 Amplification of Cp/Wp- 
derived EBNA1 cDNA 
(Fig. 7) 




Amplification of EBNA2 
cDNA (Fig. 4) 
EBNA3C-Rev EBNA3C exon 
BERF4 
GGAGATGTTAGAAGCCAATGTC 86683-86662 Amplification of EBNA3C 
cDNA (Figs. 4, 6) 
BHRF1-Rev BHRF1 exon HF TCCCGTATACACAGGGCTAACAGT 42134-42111 Amplification of BHRF1 
cDNA (Fig. 8) 
     
TaqMan™ Probes 
 
   
Unique-BHLF1 BHLF1 unique 
domain 
CTTGCCTGGTCCTGGAGCTCATC 40079-40101 Detection of BHLF1  
cDNA (Fig. 2) 
 
P2/P3'-BHLF1 Between P1 & P2 TACCTACCTCTAGGCTCCACCCAC 40820-40797 Detection of P2/P3'-
BHLF1 cDNA (Figs. 2, 5) 
 
P3'-BHLF1 Between P2 & P3' CCGGGACGTGGTGCTTCCTAAA 41400-41379 Detection of P3'-BHLF1 
cDNA (Figs. 2, 5) 
 
SM SM ACCGTGGTTTGACATGAGTCTGGTT 71271-71247 Detection of SM cDNA 
(Fig.2) 
 
BHRF1 BHRF1 HF exon AATAGGCCATCTTGCTCTACAAGATCTGGCA 42097-42067 Detection of BHRF1 
cDNA (Fig. 8) 
     
aPrimers and probes used for assessment of GAPDH mRNA and EBV miRNAs were obtained from and used in conjunction with commercially 
obtained RT-qPCR kits (see Material and Methods), and are not listed here. 
bBased on B95.8-Raji composite EBV genome sequence, accession number NC_007605.1 
cGSP: gene-specific primer used for synthesis of cDNA by reverse transcription 
dFwd: forward/5' PCR primer; Rev: reverse/3' PCR primer 
eN/A, not applicable    
fBased on Akata EBV genome sequence, accession number KC_207813 
 
 
Figure 1. Organization of the gene locus for BHLF1 and that of its paralog, LF3. The EBV 
genome (top) is shown in its linear configuration (not to scale) bounded by its terminal repeats 
(TR); major internal direct repeat elements (IR1-IR4) and the origin of EBV DNA replication 
utilized during latency (oriP) are shown for reference, as are the common EBNA promoters Cp 
and Wp, and the EBNA1-only promoter Qp. The BHLF1 and LF3 genes overlap the two highly 
homologous origins of EBV DNA replication, oriLytLeft and oriLytRight, respectively, active during 
productive (lytic) infection. In some EBV genomes a long ORF (colored arrows) is present within 
the transcribed regions of BHLF1 and LF3 that are composed primarily of related direct repeats 
(vertical lines) of 125 (IR2) and 102 (IR4) bp, respectively; copy numbers of IR2 and IR4 repeats 
may vary and are based here on the complete composite EBV genome derived from the B95.8 
and Raji isolates of EBV (accession number NC_007605.1). The ~1 kbp duplicated-sequence 
domains DSL and DSR that encompass oriLytLeft and oriLytRight, respectively, are underscored by 
the green bar. Solid horizontal arrows depict the previously characterized transcripts that are 
highly expressed from the BHLF1 and LF3 P1 promoters upon induction of the EBV replicative 
cycle, and which are unspliced and polyadenylated at sites indicated by short vertical arrows. 
Transcription start sites upstream of P1 that implicate latency-specific promoters have been 
mapped by nuclease-protection assay (P2) or were localized by RT-PCR (P3', P3 and P4) (32). 
The structures of these transcripts have not been defined, and thus are represented here as 
dashed arrows 3' co-terminal with the P1 transcripts from either locus. The ΔBHLF1 and ΔB-S 
deletions within mutant rEBVs used in this study are depicted below the expanded BHLF1 
locus. 
 
Figure 2. Widespread expression of BHLF1 RNA in latently infected B-cell lines. RT-qPCR was 
used with three different primer sets to determine the relative level of BHLF1 transcripts within 
B-cell lines that maintain Lat I or III, or in Akata BL-derived Lat I lines (A.21 and BX1) that had 
been treated by cross-linking of surface IgG to induce the EBV replication cycle. (A) BHLF1 
RNAs (left panel) were amplified with a primer set specific for the unique-sequence domain 
(Unique BHLF1) immediately upstream of the IR2 repeats within the known BHLF1 mRNA and 
not present within RNAs encoded by LF3. Levels of SM transcripts were determined in parallel 
(right panel) to provide an indication of the degree of EBV lytic-cycle gene transcription 
supported in each cell line. Level of expression shown for both BHLF1 and SM transcripts is 
relative to that of the respective RNA in Ak-LCL cells (Lat III), which was arbitrarily set at 1.0. (B) 
In addition to the primer set used to obtain the BHLF1 results in (A), primer sets expected to 
detect the putative latency-specific transcripts initiating from P2 or P3' (P2/P3') or P3' were 
used. Because these primers target the duplicated sequence elements present in the highly 
homologous BHLF1 and LF3 loci, RNA from MH-LCL cells was used as a reference, since the 
genome of the B95.8 isolate of EBV within this LCL lacks the LF3 locus, a consequence of a 
11.5-kbp deletion. Conversely, the BHLF1 locus is absent from the EBV genomes within the Sal 
BL line, also due to a naturally occurring deletion; consequently, amplification of RNA from Sal 
cells with the P2/P3' and/or P3' primer sets would be indicative of LF3 transcription. The relative 
positions of the primer sets employed for reverse transcription and qPCR are shown as shaded 
bars in relation to their position within the various BHLF1 transcripts (see diagram). Kem I, Mutu 
I, A.21 and BX1 maintain Lat l; Ak-LCL, Kem III and MH-LCL maintain Lat III. Sal cells support 
Wp-restricted latency (Lat III, but minus expression of EBNA2, LMP1 and LMP2). BL2 and A.2 




Figure 3. BHLF1 protein expression is enhanced by SM. EBV-negative Louckes BL cells were 
co-transfected with an expression vector encoding FLAG-tagged BHLF1 (origin: B95.8 EBV 
DNA) and 5 or 10 µg of expression vector for the EBV SM protein, or the empty pcDNA3 
expression vector. Symbols +, - and the closed triangle indicate the presence, absence, or 
increasing amount of the indicated expression vector, respectively. All transfections contained 
an equal amount of plasmid DNA, adjusted with empty expression vector (20 µg total plasmid 
DNA, lanes 1-3; 10 µg total plasmid DNA, lanes 4 and 5). Protein expression was detected by 
immunoblotting for the FLAG epitope (BHLF1 and insulin degrading enzyme [IDE], a positive 
control for detection of FLAG), or α-actin (gel-loading control). Results are representative of four 





Figure 4. The BHLF1 locus is required to sustain Lat III. (A) Immunoblot detection of EBV 
latency-associated proteins expressed in BL2 cells at 30 and 68 days post infection (dpi) with 
either WT or ΔB-S rEBV revealed a shift from Lat III to a Lat I-specific pattern of EBV protein 
expression (EBNA1 only) in cells infected with the BHLF1- rEBV. All BL2 cell lines (nos. 1-6) 
resulted from independent infections by the WT or mutant rEBV. Detection of α-actin or β-
tubulin served as loading controls. (B) Analysis of EBNA1 promoter usage by endpoint RT-PCR 
at 28, 41 and 68 dpi revealed a shift from Cp/Wp- to Qp-driven EBNA1 mRNA expression (Lat 
III to Lat I) in BL2 cells infected with ΔB-S rEBV, and corresponded to the loss of Lat III-specific 
protein expression as seen in (A). Amplification of EBNA1 cDNAs generated from the RNA of 
Kem I (Lat I), Kem III (Lat III) and BL2 (EBV-negative) cells served as controls. (C) A similar 
decrease in EBNA2 and EBNA3C mRNA expression was detected in BL2 cells when infected 
with ΔB-S but not with WT rEBV. 
 
 
Figure 5. BHLF1 RNA levels within six independently derived BL2 cell lines at approximately 1 
month p.i. with either WT or ΔB-S rEBV were determined by RT-qPCR in triplicate; error bars 
indicate the standard deviation. Values are relative to the level of RNA in MH-LCL (LF3-) 
determined with primer sets specific for transcripts initiating at P2 and/or P3' (P3'-initiating 
transcripts may overlap those from P2), or at P3' alone (see diagram, Fig. 2B). RNA from BL2 
cells infected with ΔB-S rEBV (BHLF1-, LF3+) was included to help exclude the possibility that 
products amplified with the P2/P3' and P3' primer sets had originated from the highly 
homologous LF3 locus. Comparable results were obtained in separate experiments when 
amplification was done using a primer set specific for the unique-sequence domain of BHLF1 




Figure 6. rEBV lacking the BHLF1 ORF alone is unable to sustain Lat III. EBV latency-
gene expression was assessed in BL2 cells infected with ΔBHLF1 rEBV at 18-386 dpi, as 
described in the legend for Fig. 4. (A) Detection of EBNA and LMP1 expression by 
immunoblotting. (B) Detection by endpoint RT-PCR of EBNA1 mRNAs from Cp/Wp or Qp, and 
of EBNA3C mRNA at 18/23, 60 and 92 dpi. The smaller EBNA3C cDNA bands detected at 60 
and 92 dpi in ΔBHLF1 rEBV-infected cell line no. 2 were determined by DNA sequence analysis 
to be splicing variants of the EBNA3C mRNA. BL2 cells infected in parallel with WT rEBV failed 




Figure 7. BHLF1 contributes to but is not essential for transition to Lat I in BL30 BL cells. 
EBV-negative BL30 cells were infected with either WT, ΔBHLF1 or ΔB-S rEBV, and cell lines 
resulting from six independent infections with each virus were assessed by RT-PCR for Cp/Wp 
(Lat III) and Qp (Lat I) usage at 1 and 3 months p.i. (mpi). Results indicated that BL30 cells 
infected with WT rEBV were able to support Lat I, but their apparent transition to Lat I was 
generally delayed relative to cells infected with either BHLF1- virus. (A) Detection by endpoint 
RT-PCR (35 cycles) of Cp/Wp usage for EBNA1 mRNA expression in six cell lines at 1 and 3 
mpi with either WT, ΔBHLF1 or ΔB-S rEBV. GAPDH mRNA was amplified in parallel as a 
control for RNA integrity. Kem I (Lat I), Kem III (Lat III) and uninfected BL30 cells served as 
controls. (B) Cell lines 3, 4 and 5 from each infection were reassessed by endpoint RT-PCR at 
30 cycles to highlight the generally delayed transition (loss of Cp/Wp usage) to Lat I in BL30 
cells infected with WT rEBV, as in WT lines 4 and 5. The smaller, sub-molar amplification 
product seen in (A) and (B) represents an alternatively-spliced transcript, which complicates 
assessment by RT-qPCR. (C) Quantification by RT-qPCR of Qp usage for EBNA1 mRNA 
expression indicative of Lat I. Data were analyzed by the ΔΔCT method with expression values 
normalized to GAPDH mRNA; the Qp values for Kem I cells (Lat I) were set at 1. Note that the 
expression scale is different in the bottom panel due to higher amounts of Qp-derived 




Figure 8. Deletion of the BHLF1 locus does not negatively impact expression of BHRF1 mRNA. 
Expression of the latency-associated BHRF1 mRNA was analyzed by RT-qPCR at 1 month p.i. 
with either: (A) WT versus ΔB-S rEBV; or (B) WT versus ΔBHLF1 rEBV. Each of the six WT 
lines in (A) are distinct from the six WT lines in (B), i.e., a total of twelve independent BL2 lines 
infected with WT rEBV were analyzed. Each bar represents the mean relative level of 
expression determined, in triplicate, for the BHRF1 mRNA in the tested line relative to the 
respective BHRF1 mRNA level (set at 1.0) in the Lat III reference line Ak-LCL. The forward (5') 
PCR primers used were specific for either the W2 or Y2 exon present within EBNA and BHRF1 
mRNAs expressed from either Cp or Wp. The Wp-restricted BL line Sal was included as an 
additional reference, as it contains a deletion in its endogenous EBV genomes that removed the 
DNA encoding the Y2 exon, rightward through EBNA2 and BHLF1, to the same relative 3' 
coordinate as the deletion within ΔB-S rEBV (consequently, Y2-exon-specific detection of 




Figure 9. Deletion of the BHLF1 locus does not impact expression of BHRF1 miRNAs. 
Expression of miR-BHRF1-1, miR-BHRF1-2 and miR-BHRF1-3 at 1 month p.i. was assessed by 
RT-qPCR for the same BL2 cells as analyzed for BHRF1 mRNA expression in Fig. 8. BL2 cells 
were infected with: (A) WT or ΔB-S rEBV; or (B) WT or ΔBHLF1 rEBV. Each bar represents the 
mean relative level of expression determined, in triplicate, for each of the three BHRF1 miRNAs 
relative to the respective BHRF1 miRNA level (set at 1.0) in the Lat III reference line Ak-LCL. 
miR-BHRF1-1 is absent in BL2 cells infected with ΔB-S rEBV and the BL line Sal due to the 
introduced or naturally occurring deletions in the EBV genomes within these lines, respectively. 
Error bars indicate the standard error of the means. 
 
Figure 10. BHLF1 contributes to EBV-
mediated B-cell immortalization. Primary B 
lymphocytes from four adult donors were 
infected in vitro with either WT, ΔB-S (donor 
1 and 4 only) or ΔBHLF1 rEBV at the 
indicated multiplicity of infection (MOI). 
Immortalization was scored at six weeks p.i. 
and is presented as percent of wells out of 
eight for each MOI that exhibited outgrowth 
of cells. The paired WT1 and ΔB-S, and WT2 
and ΔBHLF1 infections of donor 1 B cells 
were done at different times (cells were 
frozen for later infection with WT and 
ΔBHLF1 rEBVs). Unlike for B cells from 
donors 1, 3 and 4, donor 2 B cells were 
equivalently susceptible to immortalization by 
WT or ΔBHLF1 rEBVs; however, donor 2 
cells were ~3-4 times more sensitive to 





Figure 11. B lymphocytes immortalized with ΔBHLF1 rEBV exhibit reduced growth properties. 
Shown are representative growth curves of three B LCLs immortalized by WT rEBV (top), and 
four immortalized by infection with ΔBHLF1 rEBV (bottom). All LCLs were derived from B-cell 
donor 3 (Fig. 10). Cells were seeded in triplicate at 1 x 105 cells per ml, and the mean viable-cell 




Figure 12. The BHLF1 locus is uniformly transcribed during Lat III. Single-cell RNA-seq analysis 
of the EBV transcriptome in ten cells of the B LCL GM12878, immortalized by the B95.8 isolate 
of EBV, indicated that BHLF1 transcripts were present in each cell. This was in contrast to 
heterogeneous detection of transcripts encoded by known latency-associated genes, e.g., 
EBNA1, LMP2A/2B, EBNA2 and LMP1 (note that transcripts from the latter two genes were not 
evident in this figure due to the scale used for the vertical axis). Other peaks represent various 
lytic-cycle transcripts. The results shown were obtained by analysis, as described (80), of 
publically available datasets from https://www.encodeproject.org/experiments/ENCSR673UIY/  
(71). 
